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Neuromuscular	  diseases	  include	  a	  wide	  range	  of	  acquired	  or	  inherited	  conditions	  
mainly	  affecting	  the	  motor	  neurons	  in	  the	  spinal	  cord,	  peripheral	  motor	  nerves,	  
and/or	  the	  muscles.	  
The	  overall	  estimated	  prevalence	  of	  the	  various	  inherited	  neuromuscular	  diseases	  
(including	  the	  most	  common	  forms	  of	  muscular	  dystrophy,	  proximal	  spinal	  
muscular	  atrophies,	  and	  the	  hereditary	  motor	  and	  sensory	  neuropathies)	  among	  
both	  sexes	  is	  approximately	  1	  in	  3500	  in	  the	  general	  population,	  according	  to	  a	  
meta-­‐analysis	  of	  over	  150	  published	  studies	  (Emery	  AE,	  1991).	  
Although	  medical	  interventions	  have	  increased	  the	  life	  span	  and	  improved	  the	  
quality	  of	  life	  for	  many	  of	  these	  diseases,	  at	  present	  there	  is	  still	  no	  cure	  for	  most	  
neuromuscular	  diseases,	  and	  many	  familiar	  cases	  still	  remains	  with	  no	  genetic	  
diagnosis.	  
The	  recent	  advances	  in	  genetics	  together	  with	  the	  widespread	  availability	  of	  whole	  
genome	  and	  exome	  sequencing	  has	  effectively	  removed	  many	  obstacles	  in	  the	  
process	  of	  disease	  gene	  identification,	  like	  the	  need	  of	  large	  pedigrees.	  
Disease	  gene	  identification	  allows	  to	  the	  development	  of	  cell	  culture	  and	  animal	  
models	  for	  delineating	  disease	  mechanisms,	  and	  it	  facilitates	  the	  identification	  of	  
targets	  for	  therapeutic	  intervention.	  
The	  overall	  purpose	  of	  my	  PhD	  research	  is	  to	  investigate	  the	  causes	  of	  hereditary	  
neurological	  diseases,	  with	  the	  goal	  of	  developing	  effective	  treatments	  for	  these	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disorders.	  This	  purpose	  is	  pursued	  through	  two	  strategic	  aims:	  (1)	  To	  identify	  and	  
characterize	  novel	  disease	  genes	  for	  hereditary	  neuromuscular	  and	  
neurodegenerative	  disorders.	  (2)	  To	  develop	  and	  evaluate	  potential	  therapeutic	  
agents	  for	  spinal	  and	  bulbar	  muscular	  atrophy	  (SBMA).	  
	  
Specific	  aim	  1.	  To	  identify	  and	  characterize	  novel	  disease	  genes	  for	  hereditary	  
neuromuscular	  and	  neurodegenerative	  disorders	  
Charcot-­‐Marie-­‐Tooth	  disease	  (CMT)	  defines	  a	  clinically	  and	  genetically	  
heterogeneous	  group	  of	  hereditary	  peripheral	  neuropathies	  characterized	  by	  
chronic	  motor	  and	  sensory	  impairment.	  Charcot-­‐Marie-­‐Tooth	  disease	  is	  the	  most	  
common	  hereditary	  neuromuscular	  disorder,	  with	  a	  prevalence	  of	  ~1	  in	  2,500	  
people	  (Skre,	  1974).	  	  Approximately	  7-­‐10%	  of	  CMT	  is	  inherited	  as	  an	  X-­‐linked	  trait	  
(CMTX)	  (Pareyson,	  2009).	  We	  have	  evaluated	  a	  large	  Italian-­‐American	  family	  with	  a	  
slowly	  progressive,	  childhood-­‐onset,	  X-­‐linked	  recessive	  axonal	  neuropathy	  with	  
deafness	  and	  cognitive	  impairment.	  By	  using	  the	  means	  of	  next	  generation	  
sequences,	  we	  have	  found	  that	  mutation	  in	  AIFM1	  causes	  this	  form	  of	  CMTX.	  	  
	  
Specific	  aim	  2.	  To	  develop	  and	  evaluate	  potential	  therapeutic	  agents	  for	  spinal	  and	  
bulbar	  muscular	  atrophy	  (SBMA).	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Spinal	  and	  bulbar	  muscular	  atrophy	  (SBMA)	  is	  an	  inherited	  motor	  neuron	  
disease	  caused	  by	  a	  trinucleotide	  (CAG)	  repeat	  expansion	  in	  the	  androgen	  receptor	  
(AR)	  gene	  on	  the	  X	  chromosome	  (La	  Spada	  et	  al,	  1991).	  	  
To	  accomplish	  Specific	  aim	  2,	  I	  have	  used	  a	  transgenic	  mouse	  model	  carrying	  the	  
full-­‐length	  human	  AR	  containing	  97	  CAGs,	  gift	  of	  Dr.	  Sobue.	  These	  mice	  
demonstrated	  progressive	  motor	  impairment	  and	  neuropathologic	  changes	  
equivalent	  to	  human	  SBMA	  and	  are	  an	  established	  model	  of	  the	  disease	  (Katsuno	  ,	  
2002).	  We	  have	  investigated	  the	  efficacy	  of	  treatment	  with	  recombinant	  human	  
IGF-­‐1	  in	  complex	  with	  IGFBP-­‐3	  (Iplex,	  mecasermin	  rinfabate),	  based	  on	  strong	  in	  
vitro	  evidence	  that	  IGF-­‐1	  reduces	  toxicity	  of	  the	  expanded	  polyglutamine	  AR,	  in	  a	  
manner	  dependent	  upon	  phospho-­‐inositol-­‐3-­‐kinase	  (Palazzolo,	  2007).	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Cowchock	  syndrome	  (CMTX4)	  is	  a	  slowly	  progressive	  X-­‐linked	  recessive	  
disorder	  with	  axonal	  neuropathy,	  deafness,	  and	  cognitive	  impairment.	  The	  disease	  
locus	  was	  previously	  mapped	  to	  an	  11	  cM	  region	  at	  chromosome	  Xq24-­‐q26.	  Exome	  
sequencing	  of	  a	  patient	  from	  the	  originally	  described	  family	  identified	  a	  missense	  
change	  c.1478A>T	  (p.Glu493Val)	  in	  AIFM1,	  the	  gene	  encoding	  apoptosis-­‐inducing	  
factor	  (AIF)	  mitochondrion-­‐associated	  1.	  The	  change	  is	  at	  a	  highly	  conserved	  
residue	  and	  co-­‐segregated	  with	  the	  phenotype	  in	  the	  family.	  AIF	  is	  an	  FAD-­‐
dependent	  NADH	  oxidase	  that	  is	  imported	  into	  mitochondria.	  With	  apoptotic	  
insults,	  a	  N-­‐terminal	  transmembrane	  linker	  is	  cleaved	  off,	  producing	  a	  soluble	  
fragment	  that	  is	  released	  into	  the	  cytosol	  and	  then	  transported	  into	  the	  nucleus,	  
where	  it	  triggers	  caspase-­‐independent	  apoptosis.	  Another	  AIFM1	  mutation	  that	  
predicts	  p.Arg201del	  has	  recently	  been	  associated	  with	  severe	  mitochondrial	  
encephalomyopathy	  in	  two	  infant	  patients	  by	  impairing	  oxidative	  phosphorylation.	  
The	  c.1478A>T	  (p.Glu493Val)	  mutation	  found	  in	  the	  family	  reported	  here	  alters	  the	  
redox	  properties	  of	  the	  AIF	  protein	  and	  results	  in	  increased	  cell	  death	  via	  apoptosis,	  
without	  affecting	  the	  activity	  of	  the	  respiratory	  chain	  complexes.	  Our	  findings	  
expand	  the	  spectrum	  of	  AIF-­‐related	  disease	  and	  provide	  new	  insights	  into	  the	  
effects	  of	  AIFM1	  mutations.	  
Materials	  and	  Methods	  
Exome	  data	  analysis.	  Libraries	  were	  prepared	  using	  NimbleGen	  SeqCap	  EZ	  Exome	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Library	  SR	  (Roche/Nimblegen,	  WI,	  USA)	  as	  per	  the	  manufacturer’s	  protocol.	  
Libraries	  were	  diluted	  in	  Qiagen	  Buffer	  EB	  (Qiaquick	  PCR	  Purification	  Kit)	  to	  a	  
concentration	  of	  6.5	  pM.	  Next	  generation	  sequencing	  was	  performed	  (50	  bp,	  paired	  
end)	  on	  an	  Illumina	  HiSeq2000	  with	  each	  sample	  exome	  library	  on	  a	  single	  lane	  of	  
an	  Illumina	  TruSeq	  v2	  flowcell	  (Illumina,	  CA,	  USA).	  Variants	  not	  shared	  between	  all	  
affected	  individuals	  in	  the	  family	  studied,	  and	  variants	  that	  are	  non-­‐autosomal,	  
homozygous,	  and	  synonymous	  were	  excluded.	  	  Variants	  reported	  in	  SeattleSeq	  with	  
a	  frequency	  of	  >	  0.05%	  NHBLI	  Exome	  Sequencing	  Project	  (ESP)	  database	  
(http://evs.gs.washington.edu/EVS/)	  were	  also	  excluded.	  Variants	  remaining	  after	  
exome	  data	  analysis	  containing	  missing	  data	  were	  Sanger	  sequenced	  using	  the	  Big-­‐
Dye	  Terminator	  v3.1	  chemistry	  (Applied	  Biosystems,	  CA),	  run	  on	  an	  ABI	  3730xl	  
analyzer,	  and	  analyzed	  using	  Sequencer	  software	  version	  4.2	  (Gene	  Codes,	  MI).	  
Crystallization	  of	  AIFE493V.	  AIFE493V	  was	  crystallized	  by	  a	  microbatch	  method	  under	  
oil.	  The	  protein	  (0.6	  μl,	  12	  mg⁄ml)	  in	  100	  mM	  BisTris	  propane	  buffer,	  pH	  7.5,	  was	  
mixed	  with	  0.6	  μl	  of	  the	  crystallization	  solution	  containing	  30%	  polyethylene	  glycol	  
1500,	  0.1	  M	  Tris	  pH	  8.5,	  and	  4%	  acetone,	  and	  then	  covered	  with	  10	  μl	  of	  paraffin	  
oil.	  Crystals	  grew	  within	  several	  days	  at	  room	  temperature.	  X-­‐ray	  diffraction	  data	  
were	  collected	  at	  the	  Stanford	  Synchrotron	  Radiation	  Laboratory	  (SSRL)	  beamline	  7-­‐
1	  using	  paratone-­‐N	  as	  a	  cryoprotectant.	  The	  structure	  was	  solved	  by	  molecular	  





Charcot-­‐Marie-­‐Tooth	  disease	  (CMT)	  defines	  a	  clinically	  and	  genetically	  
heterogeneous	  group	  of	  hereditary	  peripheral	  neuropathies	  characterized	  by	  
chronic	  motor	  and	  sensory	  impairment.	  Charcot-­‐Marie-­‐Tooth	  disease	  is	  the	  most	  
common	  hereditary	  neuromuscular	  disorder,	  with	  a	  prevalence	  of	  ~1	  in	  2,500	  
people.1	  	  Approximately	  7-­‐10%	  of	  CMT	  is	  inherited	  as	  an	  X-­‐linked	  trait	  (CMTX).2,3	  
Among	  the	  five	  known	  CMTX	  loci,	  the	  causal	  genes	  have	  been	  identified	  only	  for	  
CMTX1	  (MIM	  *304040)4	  and	  CMTX5	  (MIM	  *311850).5	  
In	  1985	  Cowchock	  et	  al	  reported	  a	  large	  Italian-­‐American	  family	  with	  a	  slowly	  
progressive,	  childhood-­‐onset,	  X-­‐linked	  recessive	  axonal	  motor	  and	  sensory	  
neuropathy	  associated	  with	  deafness	  and	  cognitive	  impairment.6	  By	  linkage	  
analysis,	  the	  disease	  locus	  was	  mapped	  to	  an	  11	  cM	  region	  at	  chromosome	  Xq24-­‐
q26	  (CMTX4	  [MIM	  %310490]).7,8	  We	  recently	  re-­‐evaluated	  this	  family	  and	  identified	  
a	  mutation	  in	  a	  candidate	  gene	  in	  this	  interval.	  The	  subjects	  were	  enrolled	  in	  an	  
institutional	  review	  board	  approved	  protocol	  of	  the	  National	  Institute	  of	  
Neurological	  Disorders	  and	  Stroke	  (NINDS),	  and	  informed	  consent	  was	  obtained	  
from	  all	  living	  subjects.	  	  
The	  most	  consistently	  observed	  clinical	  abnormalities	  were	  distal	  muscle	  
wasting,	  weakness,	  and	  sensory	  loss,	  with	  lower	  greater	  than	  upper	  limb	  
involvement.	  Only	  males	  displayed	  the	  phenotype,	  consistent	  with	  an	  X-­‐linked	  
recessive	  mode	  of	  inheritance	  (Figure	  1A).	  As	  described	  previously,6	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electrophysiological	  studies	  in	  affected	  individuals	  showed	  evidence	  of	  motor	  more	  
than	  sensory	  axonal	  neuropathy.	  Bilateral	  sensorineural	  hearing	  loss	  was	  also	  
present	  in	  three	  subjects.	  Diminished	  intellectual	  abilities	  had	  been	  noted	  in	  several	  
affected	  individuals	  since	  childhood.	  	  
Laboratory	  investigations	  in	  two	  affected	  individuals	  (III-­‐6	  and	  III-­‐9)	  showed	  
elevation	  of	  serum	  transaminases	  (up	  to	  2x),	  lactate	  dehydrogenase	  (up	  to	  440	  U/L,	  
normal	  values	  113-­‐226),	  and	  creatine	  kinase	  (up	  to	  1169	  U/L,	  normal	  values	  52-­‐
386).	  Blood	  pyruvate	  and	  free	  and	  total	  carnitine	  were	  normal.	  Cranial	  MRI	  in	  two	  
subjects	  (III-­‐3	  and	  III-­‐9)	  showed	  multiple	  punctate	  T2	  hyperintensities	  in	  the	  
supratentorial	  white	  matter	  (Figure	  1B).	  Muscle	  biopsy	  (left	  biceps;	  subject	  III-­‐9)	  
showed	  modest	  signs	  of	  neurogenic	  atrophy	  (Figure	  1C-­‐E),	  with	  no	  ragged-­‐red	  
fibers	  by	  modified	  Gomori	  trichrome	  staining	  and	  no	  abnormalities	  in	  histochemical	  
staining	  for	  cytochrome	  oxidase	  and	  succinate	  dehydrogenase	  (not	  shown).	  
Electron	  microscopy	  showed	  an	  increased	  number	  of	  mitochondria	  mainly	  in	  the	  
subsarcolemmal	  areas,	  with	  moderate	  abnormality	  of	  mitochondrial	  shape	  and	  
internal	  structure	  (Figure	  1F).	  
We	  performed	  exome	  capture	  on	  one	  patient	  using	  SureSelect	  Human	  All	  Exome	  
Kit	  v.1	  (Agilent	  Technologies	  Inc.)	  and	  sequencing	  using	  a	  Genome	  Analyzer	  IIx	  
(Illumina	  Inc.).	  The	  exome	  sequencing	  covered	  74.3%	  of	  targeted	  regions	  with	  a	  
read	  depth	  >20	  x.	  Read	  alignment	  was	  performed	  to	  the	  human	  genome	  assembly	  
hg19.	  We	  filtered	  variants	  to	  exclude	  HapMap	  SNPs	  present	  in	  dbSNP132	  that	  had	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an	  average	  heterozygosity	  greater	  than	  0.02.	  This	  approach	  left	  a	  single	  candidate	  
variant	  within	  the	  disease	  locus	  at	  position	  g.129,265,745,	  which	  predicts	  a	  
c.1478A>T	  change	  (p.Glu493Val)	  in	  the	  AIFM1	  gene	  (MIM	  *300169).	  	  
To	  confirm	  the	  AIFM1	  mutation,	  we	  used	  Sanger	  sequencing	  to	  screen	  5	  affected	  
(II-­‐3,	  III-­‐3,	  III-­‐5,	  III-­‐7,	  and	  III-­‐9)	  and	  9	  unaffected	  (I-­‐1,	  I-­‐2,	  II-­‐1,	  II-­‐2,	  II-­‐5,	  II-­‐8,	  III-­‐2,	  and	  
III-­‐4)	  family	  members	  (Figure	  1A).	  All	  clinically	  affected	  subjects	  were	  hemizygous	  
and	  all	  mothers	  of	  affected	  individuals	  were	  heterozygous	  for	  the	  c.1478A>T	  
(p.Glu493Val)	  variant	  (Figure	  1G).	  None	  of	  the	  other	  unaffected	  subjects	  had	  this	  
variant.	  Thus,	  the	  mutation	  in	  AIFM1	  completely	  co-­‐segregated	  with	  the	  CMT	  
phenotype.	  The	  Glu-­‐493	  residue	  is	  conserved	  across	  multiple	  species	  (Figure	  1H),	  
and	  the	  Val-­‐493	  variant	  was	  absent	  in	  712	  control	  individuals	  in	  the	  ClinSeqTM	  
cohort.9	  No	  mutation	  in	  AIFM1	  was	  found	  in	  102	  unrelated	  males	  with	  CMT	  of	  
unknown	  genetic	  cause.	  
AIF,	  a	  phylogenetically	  conserved	  mitochondrial	  flavoprotein,	  is	  one	  of	  the	  key	  
caspase-­‐independent	  death	  effectors.10-­‐12	  The	  AIF	  precursor	  protein	  is	  a	  nuclear-­‐
encoded	  67	  kDa	  polypeptide,	  which,	  after	  cleavage	  of	  the	  N-­‐terminal	  mitochondrial	  
targeting	  sequence,	  is	  post-­‐translationally	  inserted	  into	  the	  inner	  mitochondrial	  
membrane,	  with	  the	  N-­‐terminus	  facing	  the	  matrix	  and	  the	  C-­‐terminal	  catalytic	  
domain	  exposed	  to	  the	  intermembrane	  space.13	  Upon	  apoptotic	  insult,	  the	  
membrane	  linker	  of	  AIF	  is	  cleaved	  off,	  and	  a	  soluble	  57	  kDa	  C-­‐terminal	  fragment	  is	  
released	  into	  the	  cytosol	  and	  transported	  into	  the	  nucleus,	  where	  it	  triggers	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caspase-­‐independent	  apoptosis	  with	  chromatin	  condensation	  and	  DNA	  
fragmentation.10	  While	  the	  apoptotic	  function	  of	  AIF	  has	  been	  extensively	  
investigated,	  the	  physiological	  role	  of	  the	  protein	  in	  normal	  mitochondria	  remains	  
unclear.	  AIF	  has	  been	  proposed	  to	  function	  as	  a	  superoxide-­‐generating	  NADH	  
oxidase	  or	  electron	  transferase.14,15	  Despite	  recent	  in	  vivo	  analyses	  of	  the	  metabolic	  
changes	  caused	  by	  AIF	  deficiency	  or	  defects,	  neither	  the	  substrates	  nor	  the	  
acceptor(s)	  of	  its	  redox	  activity	  have	  been	  identified	  thus	  far.	  When	  its	  co-­‐factor	  
FAD	  is	  incorporated,	  the	  protein	  has	  a	  100-­‐fold	  preference	  for	  NADH	  over	  NADPH	  
and	  forms	  dimeric	  FADH-­‐–NAD	  charge-­‐transfer	  complexes	  (CTCs),	  which	  are	  
inefficient	  for	  electron	  transfer.	  Formation	  of	  CTC	  reduces	  the	  susceptibility	  of	  the	  
N-­‐terminus	  to	  proteolysis	  and	  weakens	  the	  AIF–DNA	  interaction,	  two	  events	  critical	  
for	  initiation	  of	  caspase-­‐independent	  apoptosis.16,17	  Further	  studies	  have	  suggested	  
that	  AIF	  may	  act	  as	  a	  redox	  sensor	  with	  interrelated	  physiologic	  and	  apoptotic	  
functions.18	  Insight	  into	  the	  normal	  function	  of	  AIF	  comes	  from	  the	  Harlequin	  (Hq)	  
mouse,	  a	  spontaneous	  model	  of	  AIF	  deficiency	  due	  to	  retroviral	  insertion	  into	  the	  
Aifm1	  gene.19	  The	  Hq	  model	  has	  80%	  reduction	  in	  normal	  AIF	  expression,	  and	  
decreased	  complex	  I	  and	  III	  activities	  in	  affected	  tissues,	  suggesting	  that	  AIF	  may	  
control	  the	  biogenesis	  and	  maintenance	  of	  the	  respiratory	  complexes.20,21	  Recently,	  
a	  c.del601-­‐603	  AIFM1	  mutation	  predicted	  to	  cause	  p.Arg201del	  was	  reported	  in	  
two	  male	  infants	  with	  severe	  progressive	  mitochondrial	  encephalomyopathy,	  
multiple	  defects	  of	  the	  respiratory	  chain	  activities,	  and	  increased	  caspase-­‐
independent	  apoptosis.22	  A	  second	  pathological	  AIFM1	  mutation,	  c.923G>A,	  which	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predicts	  p.Gly308Glu,	  was	  associated	  with	  prenatal	  ventriculomegaly	  and	  infantile	  
encephalomyopathy,	  primarily	  due	  to	  defects	  in	  the	  mitochondrial	  respiratory	  
chain.23	  Gly-­‐308	  is	  located	  in	  a	  conserved	  NADH-­‐binding	  region,	  suggesting	  that	  this	  
function	  may	  be	  compromised	  by	  the	  p.Gly308Glu	  substitution.	  	  
The	  negatively-­‐charged	  residue	  Glu-­‐493	  mutated	  in	  the	  family	  reported	  here	  is	  
not	  directly	  involved	  in	  FAD-­‐	  or	  NADH-­‐binding	  but	  is	  only	  10	  Å	  away	  from	  the	  
isoalloxazine	  ring	  that	  is	  the	  redox	  moiety	  of	  FAD.	  In	  oxidized	  AIF,	  Glu-­‐493	  is	  buried	  
and	  assists	  in	  folding	  of	  the	  C-­‐terminal	  regulatory	  insertion	  by	  mediating	  water-­‐
bridged	  contacts	  between	  the	  532-­‐534	  and	  581-­‐584	  peptides	  (Figure	  2A,	  B).	  The	  
Glu493Val	  mutation	  may	  weaken	  these	  interactions	  and	  lead	  to	  a	  more	  unstable	  
protein	  conformation.	  In	  NADH-­‐reduced	  AIF,	  the	  region	  surrounding	  Glu-­‐493	  
becomes	  exposed	  to	  solvent.16	  As	  seen	  in	  Figure	  2C,	  this	  surface	  is	  highly	  charged,	  
with	  several	  acidic	  residues	  clustering	  near	  the	  pyrimidine	  portion	  of	  the	  
isoalloxazine	  ring.	  This	  charge	  distribution	  is	  known	  to	  define	  the	  redox	  potential	  of	  
FAD	  and,	  consequently,	  the	  flavoprotein	  reactivity.	  The	  x-­‐ray	  structure	  of	  oxidized	  
p.Glu493Val	  AIF	  shows	  that	  this	  substitution	  at	  position	  493	  does	  not	  affect	  protein	  
folding	  but	  perturbs	  the	  electrostatic	  surface	  potential	  near	  the	  redox	  center	  and	  
changes	  the	  surface	  profile	  (Figure	  2D-­‐F).	  This,	  in	  turn,	  could	  increase	  solvent	  
accessibility	  of	  FAD	  and	  affect	  the	  redox	  reactivity	  of	  AIF.	  	  
To	  better	  understand	  the	  pathogenicity	  of	  the	  p.Glu493Val	  mutation	  identified	  in	  
the	  family	  with	  CMTX,	  several	  properties	  of	  the	  recombinant	  mutant	  protein	  were	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analyzed	  and	  compared	  to	  those	  of	  the	  wild	  type	  AIF	  and	  the	  previously	  reported	  
p.Arg201del	  variant.22	  The	  absorbance	  spectrum,	  extinction	  coefficient,	  and	  
midpoint	  redox	  potential	  of	  AIF	  were	  not	  affected	  by	  the	  p.Glu493Val	  mutation.	  
Similar	  to	  the	  wild	  type	  AIF,	  p.Glu493Val	  AIF	  has	  high	  affinity	  for	  NADH,	  binds	  the	  
cofactor	  tightly	  and	  in	  a	  stoichiometric	  fashion,	  and	  forms	  CTC	  upon	  reduction	  
(Figure	  3A).	  This	  implies	  that	  the	  NADH	  binding	  site	  in	  p.Glu493Val	  AIF	  is	  preserved.	  
Nevertheless,	  we	  observed	  different	  circular	  dichroism	  spectra,	  higher	  flavin	  
fluorescence,	  and	  a	  distinct	  proteolytic	  pattern	  of	  p.Glu493Val	  AIF	  (Supplemental	  
Figure	  1A-­‐C),	  indicating	  structural	  dissimilarities	  between	  wild	  type	  and	  mutant	  
proteins.	  
The	  most	  notable	  changes	  caused	  by	  the	  p.Glu493Val	  substitution	  were	  
observed	  in	  electron	  transfer	  ability.	  First,	  p.Glu493Val	  AIF	  has	  lower	  KM	  for	  NADH	  
(by	  20%)	  than	  wild	  type	  AIF,	  and	  becomes	  reduced	  by	  NADH	  4-­‐fold	  faster	  (Figure	  3B	  
and	  Table	  1).	  Second,	  the	  dimeric	  CTC	  produced	  by	  wild	  type	  AIF	  reacts	  with	  oxygen	  
slowly	  and	  is	  relatively	  stable,18	  whereas	  the	  half-­‐life	  (t1/2)	  of	  CTC	  produced	  by	  
p.Glu493Val	  AIF	  is	  one	  eighth	  that	  produced	  by	  the	  wild	  type	  protein	  (Figure	  3C,	  
Table	  1).	  Since	  p.Glu493Val	  AIF	  retains	  its	  ability	  to	  dimerize	  upon	  reduction	  with	  
NADH	  (Supplemental	  Figure	  1D),	  an	  effect	  of	  the	  p.Glu493Val	  substitution	  on	  
redox-­‐linked	  dimer	  formation	  can	  be	  ruled	  out.	  Finally,	  p.Glu493Val	  AIF	  more	  
efficiently	  transfers	  electrons	  to	  small	  electron-­‐accepting	  molecules	  and	  
cytochrome	  c	  (compare	  the	  kcat/KM
NADH	  values	  in	  Table	  1,	  which	  reflect	  the	  enzyme	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efficiency),	  but	  these	  redox	  reactions	  are	  partially	  uncoupled	  (~10%	  for	  p.Glu493Val	  
AIF	  vs.	  1-­‐2%	  for	  wild	  type	  AIF).	  	  
Another	  distinct	  feature	  of	  p.Glu493Val	  AIF	  is	  the	  pH-­‐dependence	  of	  its	  reaction	  
with	  NADH.	  Unlike	  wild	  type	  AIF,	  which	  accepts	  the	  hydride	  atom	  from	  NADH	  in	  a	  
pH-­‐independent	  manner,	  the	  rate	  of	  p.Glu493Val	  AIF	  reduction	  is	  notably	  affected	  
and	  increases	  by	  6-­‐fold	  at	  higher	  pH	  (Figure	  3D).	  Such	  pH	  dependence	  indicates	  
that	  reduction	  of	  p.Glu493Val	  AIF	  is	  associated	  with	  proton	  consumption,	  and	  may	  
lead	  to	  the	  formation	  of	  a	  neutral	  FAD	  hydroquinone	  (FADH2).	  The	  latter	  redox	  
species	  is	  less	  thermodynamically	  stable	  than	  an	  anionic	  hydroquinone	  (FADH-­‐)	  
formed	  by	  wild	  type	  AIF,	  which	  may	  be	  the	  reason	  for	  faster	  oxidation	  of	  
p.Glu493Val	  AIF	  by	  electron	  acceptors.	  Based	  on	  these	  experimental	  data,	  we	  
conclude	  that	  the	  Glu-­‐493	  residue	  controls	  proton	  accessibility	  to	  the	  flavin	  moiety	  
and	  modulates	  the	  redox	  reactivity	  of	  AIF.	  	  	  
Importantly,	  the	  destabilization	  and	  faster	  oxidation	  of	  the	  p.Glu493Val	  AIF	  -­‐
NADH	  complexes	  in	  vivo	  can	  determine	  the	  accumulation	  of	  AIF	  monomers	  that	  are	  
more	  prone	  to	  N-­‐terminal	  proteolysis	  and	  release	  of	  the	  soluble,	  apoptogenic	  
fragment.16,18	  Similar	  to	  p.Arg201del	  AIF,22	  the	  	  truncated	  apoptogenic	  form	  of	  
p.Glu493Val	  AIF	  has	  higher	  affinity	  for	  DNA	  than	  the	  wild	  type	  protein	  (Figure	  3E).	  
The	  lack	  of	  an	  inhibiting	  effect	  of	  NADH	  on	  the	  p.Glu493Val	  AIF-­‐DNA	  interaction,	  
which	  is	  observed	  for	  wild	  type	  AIF,18	  was	  likely	  due	  to	  rapid	  and	  complete	  
oxidation	  of	  p.Glu493Val	  AIF	  before	  the	  gel	  retardation	  experiment	  was	  over.	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We	  then	  investigated	  the	  consequences	  of	  the	  p.Glu493Val	  mutation	  in	  patient-­‐
derived	  cultured	  skin	  fibroblasts	  and	  skeletal	  muscle.	  We	  first	  showed	  that	  the	  
levels	  of	  mutant	  AIF	  in	  fibroblasts	  from	  patient	  III-­‐3	  were	  similar	  to	  those	  of	  wild	  
type	  AIF	  in	  control	  cells	  (Figure	  4A).	  Next,	  in	  order	  to	  test	  whether	  the	  p.Glu493Val	  
AIF	  variant	  is	  directly	  linked	  to	  impaired	  oxidative	  phosphorylation,	  we	  analyzed	  the	  
activity	  of	  the	  respiratory	  chain	  complexes	  in	  mutant	  fibroblast	  cell	  lines	  grown	  for	  
48	  hrs	  in	  a	  galactose-­‐rich	  (5	  mM),	  glucose-­‐free	  medium,	  a	  condition	  that	  forces	  cells	  
to	  rely	  for	  energy	  on	  mitochondrial	  respiration	  rather	  than	  glycolysis.	  The	  activity	  of	  
respiratory	  chain	  complexes	  in	  patient’s	  fibroblasts	  was	  not	  reduced	  compared	  to	  
carrier	  and	  controls	  (not	  shown).	  Likewise,	  no	  impairment	  in	  the	  respiratory	  chain	  
activities	  was	  detected	  in	  a	  muscle	  biopsy	  from	  patient	  III-­‐9	  (not	  shown).	  In	  order	  to	  
detect	  DNA	  fragmentation,	  which	  is	  a	  hallmark	  of	  apoptosis,	  we	  performed	  TUNEL	  
assay	  in	  muscle	  biopsy.	  Numerous	  apoptotic	  cells	  were	  present	  in	  the	  patient’s	  
sample,	  whereas	  little	  to	  no	  staining	  was	  detected	  in	  healthy	  control	  muscle	  (Figure	  
4B).	  
Since	  AIF	  is	  a	  caspase-­‐independent	  death	  effector,	  we	  treated	  p.Glu493Val	  AIF	  
mutant	  and	  wild	  type	  AIF	  control	  fibroblasts	  with	  staurosporine	  (1	  mM	  for	  2	  hr),	  a	  
protein-­‐kinase	  C	  inhibitor	  that	  induces	  cell	  death	  through	  the	  intrinsic,	  
mitochondria-­‐mediated	  pathway.	  We	  observed	  a	  much	  higher	  number	  of	  
morphologically	  altered	  nuclei	  in	  staurosporine-­‐treated	  p.Glu493Val	  AIF	  fibroblasts	  
as	  compared	  to	  wild	  type	  AIF	  cells	  (Figure	  4C).	  In	  cells	  pretreated	  with	  the	  general	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caspase	  inhibitor	  z-­‐VAD-­‐FMK	  (100	  μM	  for	  1/2	  hr),	  the	  staurosporine-­‐induced	  
nuclear	  abnormalities	  dropped	  to	  less	  than	  10%	  in	  control	  fibroblasts,	  but	  remained	  
as	  high	  as	  50%	  in	  p.Glu493Val	  AIF	  mutant	  cells	  (Figure	  4C),	  suggesting	  prominent	  
activation	  of	  the	  caspase-­‐independent,	  AIF-­‐specific	  cell	  death	  pathway.	  	  
In	  order	  to	  gain	  insight	  into	  p.Glu493Val	  AIF	  localization	  in	  vivo,	  8	  μm	  muscle	  
slices	  from	  patient	  III-­‐9	  and	  a	  healthy	  control	  were	  immunostained	  for	  AIF.	  
Interestingly,	  more	  AIF-­‐positive	  nuclear	  inclusions	  were	  detected	  in	  the	  patient’s	  
muscle	  than	  in	  the	  control,	  indicating	  that	  mutant	  p.Glu493Val	  AIF	  has	  higher	  
propensity	  to	  translocate	  into	  the	  nucleus	  (Figure	  4D).	  
In	  conclusion,	  we	  found	  that	  a	  missense	  mutation	  in	  AIFM1	  causes	  Cowchock	  
syndrome,	  a	  form	  of	  X-­‐linked	  recessive	  axonal	  motor	  and	  sensory	  neuropathy	  with	  
sensorineural	  hearing	  loss	  and	  cognitive	  impairment.	  According	  to	  our	  analysis,	  
p.Glu493Val	  AIF	  has	  slight	  structural	  changes	  and	  an	  abnormal	  propensity	  to	  NADH	  
reduction	  and	  O2	  oxidation,	  likely	  due	  to	  changes	  in	  the	  FAD	  protonation	  state.	  
Faster	  oxidation	  of	  p.Glu493Val	  AIF	  could	  lead	  to	  accumulation	  of	  AIF	  monomers,	  
which	  translocate	  into	  the	  nucleus,	  where	  they	  trigger	  caspase-­‐independent	  
apoptosis.	  Interestingly,	  compared	  to	  the	  previously	  described	  p.Arg201del	  
mutation,22	  the	  variant	  reported	  here	  alters	  the	  structure	  and	  redox	  properties	  of	  
AIF	  to	  a	  milder	  extent	  (Figure	  3B-­‐D	  and	  table	  1),	  which	  is	  consistent	  with	  a	  less	  
severe	  clinical	  phenotype.	  Also,	  while	  oxidative	  phosphorylation	  (OXPHOS)	  failure	  is	  
thought	  to	  play	  a	  major	  role	  in	  the	  pathophysiology	  of	  the	  p.Arg201del	  AIF-­‐related	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syndrome,22	  the	  mechanism	  of	  damage	  in	  CMTX4	  appears	  to	  be	  OXPHOS-­‐
independent	  and	  primarily	  mediated	  by	  increased	  caspase-­‐independent	  apoptosis.	  
Our	  identification	  of	  AIFM1	  as	  a	  gene	  mutated	  in	  CMT	  considerably	  broadens	  the	  
phenotypic	  spectrum	  associated	  with	  AIFM1	  mutations.	  The	  results	  presented	  here	  
also	  shed	  new	  light	  on	  the	  multiple	  pathogenic	  mechanisms	  in	  AIF-­‐related	  diseases.	  
Analysis	  of	  additional	  AIFM1	  mutations	  may	  help	  to	  further	  unravel	  the	  
pathophysiology	  of	  AIF	  defects,	  to	  identify	  proteins	  dependent	  on	  AIF	  activity,	  and	  
to	  determine	  the	  exact	  role	  of	  AIF	  in	  mitochondria.	  Considering	  the	  wide	  range	  and	  
importance	  of	  the	  cellular	  processes	  regulated	  by	  AIF,	  better	  understanding	  of	  AIF	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Figure	  1.	  Pedigree,	  brain	  imaging	  and	  skeletal	  muscle	  analysis,	  and	  Sanger	  
sequencing.	  
(A)	  Pedigree	  of	  the	  family.	  White,	  unaffected;	  black,	  affected.	  
	  (B)	  Fluid-­‐attenuated	  inversion	  recovery	  (FLAIR)	  magnetic	  resonance	  imaging	  on	  a	  
transverse	  section	  of	  supratentorial	  brain	  of	  a	  patient	  showing	  multiple	  punctate	  
hyperintensities	  in	  the	  white	  matter	  (subject	  III-­‐6).	  
(C-­‐E)	  Muscle	  biopsy	  showing	  variation	  in	  fiber	  size	  (hematoxylin	  and	  eosin	  staining,	  
C),	  esterase	  positive	  angular	  atrophic	  myofibers	  (esterase	  staining,	  D),	  and	  fiber	  
grouping	  with	  some	  targetoid	  fibers	  (nicotinamide	  adenine	  dinucleotide-­‐
tetrazolium	  reductase,	  E),	  and	  (subject	  III-­‐9).	  
	  (D)	  Electron	  microscopic	  image	  of	  muscle	  showing	  variation	  in	  shape	  and	  increase	  
in	  number	  of	  mitochondria,	  mainly	  in	  the	  subsarcolemmal	  areas	  (subject	  III-­‐9).	  
(G)	  Chromatograms	  of	  AIFM1	  showing	  the	  c.1478A>T	  (p.Glu493Val)	  variant	  
(asterisk)	  in	  patient	  (hemizygote)	  and	  carrier	  (heterozygote).	  
(H)	  Protein	  homology	  of	  AIF	  in	  various	  species.	  The	  mutation	  results	  in	  amino	  acid	  




Figure	  2.	  Structural	  comparison	  of	  the	  wild	  type	  and	  p.Glu493Val	  mutant	  of	  AIF.	  
The	  E493V	  substitution	  was	  introduced	  into	  the	  human	  AIF1	  expression	  plasmid	  
using	  Stratagene	  QuikChange	  kit.	  Expression,	  purification,	  and	  removal	  of	  the	  C-­‐
terminal	  six-­‐histidine	  affinity	  tag	  were	  carried	  out	  as	  described	  previously.18	  	  
(A)	  Position	  of	  Glu493	  (indicated	  by	  an	  arrow)	  in	  oxidized	  human	  AIFwt	  (PDB	  code	  
1M6I).	  FAD	  is	  shown	  in	  yellow	  and	  a	  partially	  disordered	  regulatory	  peptide	  is	  in	  
pink.	  
(B)	  Water-­‐bridged	  contacts	  involving	  Glu493	  hold	  the	  512-­‐533	  helical	  fragment	  of	  
the	  regulatory	  peptide	  (pink)	  close	  to	  the	  active	  site.	  	  
(C)	  Charge	  distribution	  near	  the	  flavin	  cofactor.	  Positively	  and	  negatively	  charged	  
residues	  are	  depicted	  in	  blue	  and	  red,	  respectively.	  Glu493	  is	  10	  Å	  away	  from	  FAD	  
and	  is	  part	  of	  an	  acidic	  cluster	  adjacent	  to	  the	  isoalloxazine	  ring.	  	  
(D)	  Superposition	  of	  the	  structures	  of	  the	  wild	  type	  (gray,	  PDB	  code	  1M6I)	  and	  
Glu493Val	  mutant	  of	  human	  AIF	  (green,	  PDB	  code	  4FDC).	  The	  structure	  of	  AIFE493V	  
was	  solved	  at	  2.4	  Å	  resolution.	  Data	  collection	  and	  refinement	  statistics	  are	  given	  in	  
Supplemental	  Table	  1.	  The	  valine	  side-­‐chain	  is	  shown	  in	  cyan.	  	  	  	  
(E)	  A	  magnified	  view	  at	  the	  region	  of	  AIF	  near	  the	  site	  of	  the	  p.Glu493Val	  
substitution	  demonstrating	  that	  the	  mutation	  does	  not	  alter	  the	  structure	  near	  the	  
active	  site	  of	  AIF.	  
(F)	  The	  Glu493Val	  mutation	  changes	  both	  the	  surface	  profile	  and	  electrostatic	  




Figure	  3.	  Comparison	  of	  the	  redox	  and	  molecular	  properties	  of	  the	  wild	  type	  and	  
p.Glu493Val	  and	  p.Arg201del	  mutants	  of	  AIF.	  
	  (A)	  Anaerobic	  titration	  of	  AIFE493V	  with	  NADH.	  Similar	  to	  the	  wild	  type	  protein,	  the	  
p.Glu493Val	  variant	  binds	  NADH	  tightly	  and	  produces	  a	  FADH-­‐-­‐NAD	  charge-­‐transfer	  
complex	  (CTC)	  absorbing	  in	  the	  long-­‐wavelength	  region.	  Inset	  shows	  that	  an	  
equimolar	  amount	  of	  NADH	  is	  required	  to	  fully	  reduce	  FAD.	  	  
(B)	  Kinetics	  of	  AIF	  reduction	  with	  NADH.	  Proteins	  were	  mixed	  with	  NADH	  in	  a	  
stopped	  flow	  spectrophotometer,	  and	  reduction	  of	  FAD	  was	  monitored	  at	  452	  nm.	  
The	  derived	  kinetic	  parameters	  are	  given	  in	  Table	  1.	  	  
(C)	  Kinetics	  of	  oxidation	  of	  NADH-­‐reduced	  AIF.	  Proteins	  were	  reduced	  with	  a	  4-­‐fold	  
excess	  of	  NADH	  before	  exposure	  to	  atmospheric	  oxygen.	  Flavin	  oxidation	  was	  
monitored	  at	  452	  nm.	  	  
(D)	  Effect	  of	  pH	  on	  the	  kinetics	  of	  AIF	  reduction	  with	  NADH.	  	  
(E)	  Comparison	  of	  DNA	  binding	  by	  wild	  type	  and	  mutant	  AIF.	  Proteins	  were	  
incubated	  for	  15	  min	  with	  250	  ng	  of	  100	  bp	  DNA	  ladder	  (New	  England	  Biolabs)	  in	  
the	  absence	  and	  presence	  of	  a	  20-­‐fold	  excess	  of	  NADH.	  After	  separation	  on	  a	  2%	  





Figure	  4.	  The	  p.Glu493Val	  mutant	  induces	  caspase-­‐independent	  apoptosis.	  
(A)	  Western	  blot	  analysis	  of	  patient	  (Mt)	  and	  control	  (Ct)	  skin	  cultured	  fibroblasts,	  
immunodetected	  with	  an	  antibody	  against	  AIF	  (Chemicon).	  Antibody	  against	  
subunit	  A	  of	  complex	  II	  (SDHA,	  Invitrogen)	  was	  used	  as	  loading	  control.	  
(B)	  TUNEL	  and	  DAPI	  staining	  of	  skeletal	  muscle	  nuclei	  from	  patient	  (Pt)	  and	  control	  
(N).	  A	  normal	  biopsy	  treated	  with	  DNAse	  was	  used	  a	  positive	  control	  (Ct).	  
Numerous	  TUNEL-­‐positive	  are	  present	  in	  the	  patient	  (Pt),	  whereas	  no	  TUNEL	  
positive	  nuclei	  are	  seen	  in	  the	  control	  (N).	  
(C)	  Quantification	  of	  altered	  nuclei	  in	  control	  fibroblasts	  (Ct)	  and	  in	  fibroblasts	  from	  
patient	  (Mut)	  after	  treatment	  with	  staurosporine	  (Stau)	  (1	  mM	  for	  2	  hr)	  in	  presence	  
or	  absence	  of	  Z-­‐VAD-­‐fmk	  (Z)	  (100	  μM	  for	  1/2	  hr).	  	  
(D)	  AIFM1	  (1:1000;	  Millipore,	  AB16501)	  immunostaining	  of	  cross	  section	  of	  muscle	  
biopsy	  showing	  nuclear	  localization	  of	  mutant	  AIF	  in	  a	  patient	  hemizygous	  for	  




























Table	   1.	  Redox	   properties	   and	   activities	   of	   the	   wild	   type	   and	  mutants	   of	   mature	  
human	  AIF	  
	   WT	   E493V	   ∆R201	  
ket
NADH	  (s-­‐1)	  a	   0.98	  ±	  0.02	   3.9	  ±	  0.1	   23	  ±	  0.4	  
KM
NADH	  (mM)	   1.53	  ±	  0.06	   1.23	  ±	  0.05	   0.23	  ±	  0.02	  
t1/2
CTC	  (h)b	   11	   1.4	   3.4	  
kox
NADH	  (min-­‐1)c	   0.015	  ±	  0.002	   0.12	  ±	  0.02	   0.06	  ±	  0.01	  
DCIP	  
	   	   	  
kcat	  (min
-­‐1)	   137	  ±	  18	   335	  ±	  32	   394	  ±	  28	  
KM
DCIP	  (M)	   202	  ±	  36	   97	  ±	  20	   16	  ±	  3	  
KM
NADH	  (mM)	   0.74	  ±	  0.12	   0.16	  ±	  0.04	   0.14	  ±	  0.02	  
kcat/	  KM
NADH	   185	   2,094	   2,814	  
K3Fe(CN)6	  
	   	   	  
kcat	  (min





6	  (M)	   28	  ±	  5	   26	  ±	  5	   68	  ±	  6	  
KM
NADH	  (mM)	   	   0.61	  ±	  0.10	   0.26	  ±	  0.05	   0.20	  ±	  0.03	  
kcat/	  KM
NADH	   515	   2,865	   7,320	  
Cytochrome	  c	   	   	   	  
kcat	  (min
-­‐1)	   54	  ±	  15	   35	  ±	  5	   39	  ±	  2	  
KM




NADH	  (mM)	   0.27	  ±	  0.02	   0.15	  ±	  0.02	   0.07	  ±	  0.01	  
kcat/	  KM
NADH	   200	   233	   557	  
a	  The	  rate	  constant	   for	   the	  AIF	  reduction	  with	  NADH	  determined	  by	  stopped	  flow	  
spectrophotometry	  at	  25˚C.	  
b	   The	   half-­‐lifetime	   of	   the	   FADH2-­‐NAD	   charge-­‐transfer	   complex	   (CTC)	   was	  
determined	  at	  25˚C	  in	  the	  presence	  of	  15	  µM	  AIF	  and	  60	  µM	  NADH.	  
c	  The	  rate	  of	  NADH	  oxidation	  by	  AIF	  was	  determined	  at	  25˚C.	  
All	   activities	   were	   determined	   in	   50	   mM	   phosphate	   buffer,	   pH	   7.4,	   at	   25˚C	   as	  























Supplemental	  Figure	  1.	  Effect	  of	  the	  E493V	  mutation	  on	  the	  molecular	  properties	  
of	  AIF.	  (A)	  Circular	  dichroism	  (CD)	  spectra	  indicate	  that	  replacement	  of	  Glu493	  with	  
valine	   induces	   only	   subltle	   changes	   in	   the	  AIF	   structure.	   Far	  UV	   CD	   spectra	  were	  
recorded	  in	  the	  absence	  and	  presence	  of	  a	  20-­‐fold	  excess	  of	  NADH.	  
(B)	  Flavin	  fluorescence	  in	  the	  wild	  type	  and	  mutant	  AIF.	  FAD	  is	  buried	  and	  virtually	  
non-­‐fluoresent	  in	  AIFwt.	  2-­‐	  and	  5-­‐fold	  increases	  in	  flavin	  fluorescence	  in	  the	  E493V	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and	   Δ201	   mutants,	   respectively,	   indicate	   higher	   solvent	   accessibility	   or	   partial	  
exposure	  of	  FAD.	  
(C)	  Tryptic	  digest	  of	  oxidized	  and	  NADH-­‐reduced	  AIFE493V	  and	  AIFwt.	  Oxidized	  AIFwt	  
undergoes	  proteolysis	  only	  at	  the	  Arg126-­‐Ala127	  site	  and	  runs	  on	  the	  SDS	  PAGE	  gel	  
as	  a	  single	  band	  of	  ~50	  kDa.	  The	  digest	  pattern	  indicates	  that,	  unlike	  in	  AIFwt,	  the	  C-­‐
terminal	   regulatory	   insertion	   in	   the	   E493V	   mutant	   is	   partially	   unfolded	   and	  
accessible	  to	  trypsin.	  (D)	  Redox-­‐dependent	  monomer-­‐dimer	  transition	  in	  AIFE493V	  is	  






















Supplemental	  Table	  1.	  
Data	  collection	  and	  refinement	  statistics	  
___________________________________________________________	  
Data	  statistics	  
Space	  group	   	   	   	   C2	  
Unit	  cell	  parameters	   	   	   a	  =	  102	  Å,	  b	  =	  63	  Å,	  c	  =	  102	  Å;	  
α,	  β	  =	  90°;	  γ	  =	  119°	   	  
Resolution	  range	   	   	   39.5	  –	  2.4	  (2.40	  –	  2.46)a	   	  
Total	  reflections	   	   	   148410	  (1427)	  	   	   	  
Unique	  reflections	   	   	  	   20005	   (1308)	   	   	  
Redundancy	   	   	   	   6.8	  (6.8)	   	   	   	  
Completeness	  	  	   	   	  94.2	  (88.7)	  
Average	  I/σI	   	   	   	   11.3	  (3.1)	  
Rmerge	   	   	   	   	   0.075	  (0.45)	  
Refinement	  statistics	  
Molecules	  per	  asymmetric	  unit	   1	   	  
R/Rfree
b	  	   	   	   25.5/29.7	  
r.m.s.	  deviations	  
Bond	  lengths,	  Å	   	   	   0.007	   	  















Supplemental	  Figure	  2.	  Western	  blot	  analysis	  of	  patient	  (Mt)	  and	  control	  (Ct)	  skin	  
cultured	  fibroblasts,	  immunodetected	  with	  an	  antibody	  against	  AIF	  (Chemicon).	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Antibodies	  against	  subunit	  A	  of	  complex	  II	  (SDHA,	  Invitrogen)	  and	  ß-­‐tubulin	  (Sigma)	  




Supplemental	  Figure	  3.	  The	  viability	  of	  fibroblasts	  from	  affected	  (AIF	  mut),	  carrier	  
(AIF	  mother)	  and	  control	  (ct)	  subject	  was	  assessed	  using	  CyQUANT	  Direct	  Cell	  
Proliferation	  Assay	  (Invitrogen).	  Cells	  were	  treated	  for	  2	  hours	  with	  staurosporine	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Spinal	  and	  bulbar	  muscular	  atrophy	  (SBMA),	  also	  known	  as	  Kennedy’s	  
disease	  (Kennedy	  et	  al,	  1968),	  is	  a	  slowly	  progressive	  disease	  with	  lower	  motor	  
neuron	  loss	  and	  weakness,	  atrophy,	  and	  fasciculations.	  The	  disease	  is	  caused	  by	  a	  
trinucleotide	  (CAG)	  repeat	  expansion	  in	  the	  androgen	  receptor	  (AR)	  gene	  on	  the	  X	  
chromosome	  (La	  Spada	  et	  al,	  1991),	  which	  results	  in	  an	  expanded	  polyglutamine	  
tract	  and	  an	  androgen-­‐dependent	  toxic	  gain	  of	  function	  in	  the	  mutant	  protein.	  The	  
disease	  has	  been	  reported	  across	  many	  ethnicities,	  with	  an	  estimated	  prevalence	  of	  
about	  1	  in	  40,000.	  Normal	  individuals	  will	  have	  repeat	  lengths	  between	  11	  and	  36	  
CAGs,	  and	  the	  disease	  will	  occur	  when	  this	  repeat	  length	  increases	  to	  between	  38	  
and	  62	  CAGs	  (Atsuta	  et	  al,	  2006;	  Rhodes	  et	  al,	  2009).	  We	  report	  the	  case	  of	  a	  29-­‐
year-­‐old	  male	  with	  68	  CAGs	  (see	  Case	  Report.	  In	  submission).	  Although	  there	  is	  no	  
treatment	  available	  to	  alter	  the	  progression	  of	  this	  disease,	  patients	  may	  have	  
benefit	  from	  symptomatic	  treatment.	  	  
The	  precise	  mechanism	  by	  which	  the	  expansion	  results	  in	  motor	  neuron	  
death	  is	  not	  clear,	  although	  several	  putative	  mechanisms	  have	  been	  investigated.	  
The	  toxic	  gain	  of	  function	  of	  the	  AR	  is	  dependent	  on	  androgens	  such	  as	  
testosterone	  and	  dihydrotestosterone.	  In	  addition	  to	  these	  toxic	  effects	  of	  the	  AR,	  
evidence	  of	  loss	  of	  normal	  receptor	  function	  also	  contributes	  to	  the	  disease	  
phenotype,	  with	  some	  patients	  experiencing	  gynecomastia	  and	  reduced	  fertility.	  
The	  mutant	  AR	  is	  prone	  to	  aggregation	  (Walcott	  et	  al,	  2002;	  Li	  et	  al,	  1998),	  and	  its	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effect	  on	  cellular	  signal	  transduction,	  mitochondria	  function,	  and	  axonal	  transport	  
is	  likely	  to	  be	  contributing	  to	  the	  disease	  (McCampbell	  et	  al,	  2000;	  Lieberman	  et	  al.,	  
2002;	  Ranganathan	  et	  al,	  2009;	  Katsuno	  et	  al.,	  2006).	  	  	  	  
	  
From	  AR	  functions	  to	  motor-­‐neuron	  disease:	  pathophysiology	  of	  SBMA	  	  
The	  cause	  of	  SBMA	  is	  an	  expansion	  of	  a	  trinucleotide	  CAG	  repeat,	  which	  
encodes	  the	  polyglutamine	  tract,	  in	  the	  first	  exon	  of	  the	  androgen	  receptor	  (AR)	  
gene	  (La	  Spada	  et	  al.,	  1991).	  A	  similar	  gene	  mutation	  has	  been	  detected	  in	  
Huntington’s	  disease,	  dentatorubral-­‐pallido-­‐luysian	  atrophy	  (DRPLA),	  and	  several	  
forms	  of	  spinocerebellar	  ataxias	  (Gatchel	  et	  al.,	  2005).	  Since	  CAG	  is	  translated	  to	  
glutamine,	  these	  disorders	  are	  called	  polyglutamine	  diseases.	  In	  SBMA,	  like	  in	  other	  
polyglutamine	  diseases,	  there	  is	  an	  inverse	  correlation	  between	  the	  CAG	  repeat	  size	  
and	  the	  age	  of	  onset,	  or	  the	  disease	  severity	  adjusted	  by	  the	  age	  of	  examination	  
(Doyu	  et	  al.,	  1992;	  Atsuta	  et	  al.,	  2006).	  
Although	  the	  disease-­‐causing	  proteins	  are	  expressed	  widely	  in	  the	  CNS,	  
specific	  populations	  of	  neurons	  are	  vulnerable	  in	  each	  disease,	  resulting	  in	  
characteristic	  patterns	  of	  neurodegeneration	  and	  clinical	  features	  (Zoghbi	  &	  Orr	  et	  
al.,	  2000).	  
In	  SBMA	  degeneration	  of	  anterior	  horn	  cells	  in	  the	  spinal	  cord	  of	  affected	  
individuals	  is	  observed	  (Kennedy	  et	  al.,	  1968;	  Ogata	  et	  al.,	  1994).	  Some	  affected	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males	  also	  experience	  degeneration	  of	  the	  dorsal	  root	  ganglia,	  leading	  to	  mild	  
abnormalities	  in	  sensory	  function	  in	  the	  distal	  extremities	  (Sobue	  et	  al.,	  1981;	  
Nagashima	  et	  al.,	  1988).	  Emerging	  evidence	  suggests	  that	  mutant	  AR	  may	  exert	  a	  
direct	  toxic	  effect	  on	  skeletal	  muscle:	  histological	  and	  molecular	  signs	  of	  muscle	  
pathology	  are	  detectable	  before	  the	  appearance	  of	  pathological	  abnormalities	  in	  
the	  spinal	  cord	  in	  a	  knock-­‐in	  mouse	  model	  of	  SBMA	  (Yu	  et	  al.,	  2006),	  and	  analysis	  of	  
muscle	  biopsy	  samples	  derived	  from	  SBMA	  patients	  suggests	  a	  mixed	  pathology	  
with	  both	  myopathic	  and	  neurogenic	  features	  (Soraru	  et	  al.,	  2008).	  
Unlike	  other	  polyglutamine	  diseases	  in	  which	  the	  function	  of	  the	  
unexpanded	  protein	  is	  not	  clear,	  in	  SBMA	  the	  disease	  protein	  has	  a	  well-­‐
characterized	  role	  as	  a	  ligand-­‐dependent	  transcription	  factor.	  AR	  is	  a	  member	  of	  
the	  nuclear	  hormone	  receptor	  superfamily	  and	  resides	  in	  the	  cytoplasm	  when	  
inactive,	  in	  a	  complex	  with	  heat-­‐shock	  and	  heat-­‐shock-­‐related	  proteins.	  Upon	  
binding	  with	  its	  natural	  ligands,	  testosterone	  and	  its	  more	  potent	  derivative	  
dihydrotestosterone,	  a	  number	  of	  events	  occur,	  including	  AR	  posttranslational	  
modification,	  nuclear	  translocation	  and	  DNA	  binding.	  	  These	  changes	  ultimately	  
result	  in	  AR-­‐mediated	  activation	  or	  repression	  of	  target	  genes.	  These	  changes	  occur	  
in	  concert	  with	  conformational	  modifications	  that	  result	  in	  the	  exposure	  of	  two	  co-­‐
regulator	  interaction	  surfaces,	  termed	  activation	  function-­‐1	  (AF-­‐1)	  and	  activation	  
function-­‐2	  (AF-­‐2)	  (Nedelsky	  et	  al.,	  2010).	  	  
In	  SBMA	  as	  in	  other	  polyglutamine	  diseases,	  human	  and	  mouse	  genetic	  data	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suggests	  that	  the	  disease	  mainly	  results	  from	  a	  gain-­‐of-­‐function	  mechanism,	  since	  
AR	  gene	  deletion	  in	  humans	  does	  not	  lead	  to	  a	  motor	  neuron	  disease,	  and	  a	  mouse	  
model	  employing	  expanded	  polyglutamine	  AR	  protein	  accurately	  reflect	  the	  human	  
disease,	  displaying	  restricted	  symptoms,	  lower	  motor	  neuron	  specificity	  and	  gender	  
specificity	  (Katsuno	  et	  al.,	  2002).	  Nevertheless,	  a	  loss	  of	  normal	  AR	  function	  may	  
also	  play	  a	  role	  in	  the	  pathogenesis,	  as	  suggested	  by	  the	  fact	  that	  some	  SBMA	  
patients	  show	  mild	  signs	  of	  partial	  androgen	  insensitivity	  like	  gynecomastia	  and	  
testicular	  atrophy.	  
A	  pathological	  hallmark	  of	  the	  polyglutamine	  diseases	  is	  the	  presence	  of	  
intranuclear	  and/or	  cytoplasmic	  inclusions	  of	  the	  disease	  proteins	  that	  are	  
ubiquitinated	  and	  often	  associated	  with	  various	  transcription	  factors,	  chaperones,	  
and	  proteasome	  components	  (Li	  et	  al.,	  1998).	  Since	  human	  AR	  is	  widely	  expressed	  
in	  various	  organs,	  nuclear	  accumulation	  of	  the	  pathogenic	  AR	  protein	  is	  detected	  
not	  only	  in	  the	  brain,	  but	  also	  in	  non-­‐neuronal	  tissues	  such	  as	  kidney,	  skeletal	  
muscle,	  adrenal	  gland,	  and	  scrotal	  skin.	  Although	  nuclear	  inclusions	  are	  a	  disease-­‐
specific	  histopathological	  finding,	  their	  role	  in	  the	  pathogenesis	  has	  been	  heavily	  
debated.	  Several	  studies	  suggest	  that	  the	  monomers	  and	  soluble	  oligomers	  of	  the	  
expanded	  protein	  constitute	  the	  toxic	  species	  in	  polyglutamine	  diseases	  and	  that	  
the	  intranuclear	  inclusions	  may	  rather	  indicate	  a	  cellular	  response	  coping	  with	  the	  




Although	  the	  expansion	  might	  interfere	  with	  the	  normal	  function	  of	  the	  host	  
protein,	  it	  is	  not	  yet	  clear	  how	  this	  contributes	  to	  pathogenesis.	  A	  number	  of	  
studies	  have	  indicated	  that	  transcriptional	  dysregulation	  underlies	  the	  molecular	  
mechanism	  of	  neuronal	  dysfunction	  in	  polyglutamine	  disease	  (McCampbell	  et	  al.,	  
2002;	  Minamiyama	  et	  al.,	  2004).	  CREB-­‐binding	  protein	  (CBP),	  a	  transcriptional	  co-­‐
activator	  that	  orchestrates	  the	  nuclear	  response	  to	  a	  variety	  of	  cell	  signaling	  
cascades,	  is	  incorporated	  into	  nuclear	  inclusions	  formed	  by	  polyglutamine-­‐
containing	  proteins	  in	  cultured	  cells,	  transgenic	  mice,	  and	  tissue	  from	  patients	  with	  
SBMA	  (McCampbell	  et	  al.,	  2002).	  	  Histone	  acetylation	  is	  decreased	  in	  mouse	  model	  
of	  SBMA,	  which	  may	  be	  a	  consequence	  of	  altered	  CBP	  localization	  (Minamiyama	  et	  
al.,	  2004).	  Mitochondrial	  impairment	  and	  oxidative	  stress	  have	  also	  been	  suggested	  
as	  a	  causative	  molecular	  event	  in	  SBMA	  (Ranganathan	  et	  al.,	  2009).	  Moreover,	  the	  
pathogenic	  AR	  protein	  represses	  the	  transcription	  of	  the	  subunits	  of	  peroxisome	  
proliferators-­‐activated	  receptor	  gamma	  co-­‐activator	  (PGC-­‐1),	  a	  transcriptional	  co-­‐
activator	  that	  regulates	  the	  expression	  of	  various	  nuclear-­‐encoded	  mitochondrial	  
proteins	  (Ranganathan	  et	  al.,	  2009).	  In	  the	  muscle	  of	  both	  theSBMA	  mouse	  model,	  
and	  SBMA	  patients,	  neurofilaments	  and	  synaptophysin	  accumulate	  at	  the	  distal	  
motor	  axon,	  suggesting	  an	  impairment	  of	  retrograde	  axonal	  transport	  	  (Katsuno	  et	  
al.,	  2006).	  	  
	  
Diagnostic	  studies	  and	  evaluation	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  The	  diagnosis	  is	  usually	  made	  following	  genetic	  testing,	  with	  all	  affected	  
individuals	  having	  a	  trinucleotide	  repeat	  expansion	  containing	  at	  least	  38	  CAGs	  in	  
the	  first	  exon	  of	  the	  AR	  gene	  (La	  Spada	  et	  al,	  1991).	  	  Aspartate	  and	  aspartate	  
aminotransferases	  are	  found	  to	  be	  mildly	  elevated	  above	  the	  reference	  range,	  and	  
creatine	  kinase	  is	  elevated	  in	  most	  subjects	  to	  the	  900-­‐1400	  U/l	  range	  (Atsuta	  et	  al,	  
2006;	  Rhodes	  et	  al,	  2009).	  	  SBMA	  subjects	  may	  also	  have	  impaired	  glucose	  
tolerance,	  and	  elevation	  of	  the	  low-­‐density	  lipoprotein	  levels	  above	  normal.	  
Although	  most	  patients	  can	  have	  elevations	  in	  average	  total	  testosterone,	  free	  
testosterone,	  and	  dihydrotestosterone,	  the	  levels	  of	  free	  testosterone	  and	  
dihydrotestosterone	  may	  also	  be	  reduced	  in	  some	  individuals.	  	  
The	  key	  electrodiagnostic	  features	  on	  EMG/NCS	  will	  be	  low	  sensory	  nerve	  
amplitudes,	  decreased	  compound	  motor	  action	  potentials,	  and	  evidence	  of	  diffuse	  
denervation	  atrophy.	  Motor	  unit	  nerve	  estimation	  (MUNE)	  can	  be	  reduced	  to	  about	  
half	  of	  healthy	  control	  values.	  	  A	  muscle	  biopsy	  is	  not	  needed	  to	  make	  a	  diagnosis,	  
but	  can	  show	  evidence	  of	  neurogenic	  and	  myogenic	  atrophy	  (Kennedy	  et	  al,	  1968;	  
Soraru	  et	  al,	  2008).	  	  
A	  majority	  of	  SBMA	  patients	  have	  a	  pertinent	  family	  history	  (Rhodes	  et	  al,	  
2009).	  	  Since	  SBMA	  is	  an	  X-­‐linked	  recessive	  disease,	  the	  children	  of	  affected	  
patients	  are	  asymptomatic.	  The	  disease	  may	  be	  passed	  through	  asymptomatic	  
females,	  e.g.,	  mothers,	  sisters,	  and	  daughters	  of	  affected	  patients.	  Female	  carriers	  
do	  not	  develop	  weakness,	  and	  a	  small	  number	  may	  experience	  cramping	  (Ishihara	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et	  al,	  2001).	  The	  CAG	  repeat	  may	  change	  between	  generations,	  with	  longer	  repeats	  
correlating	  to	  an	  earlier	  age	  of	  disease	  onset	  (La	  Spada	  et	  al,	  1992).	  Carriers	  and	  
those	  who	  are	  at	  risk	  of	  being	  carriers	  should	  have	  access	  to	  genetic	  counseling	  
services.	  
	  
Clinical	  Presentation	  	  
Neurological	  features	  of	  the	  disease	  usually	  begin	  during	  the	  fourth	  or	  fifth	  
decade	  of	  life,	  but	  the	  onset	  ranges	  from	  ages	  18	  to	  64	  (Rhodes	  et	  al,	  2009).	  Initial	  
symptoms	  can	  include	  tremor,	  cramping,	  and	  weakness	  (Dias	  et	  al,	  2011	  can’t	  find	  
the	  reference).	  The	  classic	  signs	  of	  lower	  motor	  neuron	  disease	  are	  typical,	  and	  
include	  reduced	  deep	  tendon	  reflexes,	  atrophy,	  and	  fasciculations	  in	  the	  muscles	  of	  
the	  extremities.	  Weakness	  will	  present	  as	  difficulty	  climbing	  stairs	  and	  walking,	  
particularly	  long	  distances.	  The	  distribution	  of	  weakness	  is	  both	  proximal	  and	  distal,	  
with	  asymmetry	  more	  frequently	  involving	  the	  dominant	  side	  (Rhodes	  et	  al,	  2009).	  
Degeneration	  of	  the	  dorsal	  root	  ganglia	  can	  result	  in	  a	  loss	  of	  sensory	  function	  in	  
the	  distal	  extremities.	  Patients	  will	  also	  typically	  have	  evidence	  of	  androgen	  
insensitivity,	  which	  can	  manifest	  as	  gynecomastia,	  oligospermia,	  and	  erectile	  
dysfunction.	  The	  interruption	  of	  normal	  androgen	  receptor	  function	  has	  been	  
shown	  to	  decrease	  the	  risk	  of	  androgenetic	  alopecia	  in	  SBMA	  (Sinclair	  et	  al,	  2007).	  	  
53	  
	  
Most	  individuals	  also	  show	  involvement	  of	  the	  bulbar	  muscles	  and	  have	  difficulty	  
with	  speech	  articulation	  and	  swallowing	  (Figure	  1).	  Dysarthria	  and	  dysphagia	  
appear	  at	  a	  median	  age	  of	  50	  and	  54	  years,	  respectively	  (Astuta	  et	  al.,	  2006).	  Other	  
symptoms	  reported	  include	  weakness	  and	  atrophy	  primarily	  involving	  the	  facial	  and	  
tongue	  muscles	  with	  perioral	  fasciculations(Figure	  2;	  video),	  and	  	  changes	  in	  voice	  
and	  speech,	  characterized	  byhypernasality	  and	  a	  decreased	  range	  of	  pitch	  and	  
loudness.	  SBMA	  patients	  may	  present	  with	  fatigue	  when	  chewing	  and	  occasionally	  
with	  jaw	  drop,	  caused	  by	  severe	  weakness	  of	  the	  jaw-­‐closure	  muscles	  (temporalis	  
and	  masseter	  muscles)	  with	  preservation	  of	  jaw-­‐opening	  muscles	  (pterygoid	  
muscles)	  (Sumner	  et	  al.,	  2002).	  	  
The	  disease	  will	  usually	  progress	  slowly,	  and	  in	  a	  recent	  clinical	  trial	  a	  2%	  
decline	  in	  muscle	  strength	  per	  year	  was	  detected	  using	  quantitative	  muscle	  
assessment	  (Fernandez-­‐Rhodes	  et	  al,	  2011).	  	  
The	  vast	  majority	  of	  individuals	  with	  SBMA	  have	  a	  normal	  life	  expectancy	  
and	  do	  not	  die	  from	  direct	  complications	  of	  thedisease.	  About	  10%	  of	  affected	  
individuals	  are	  at	  risk	  for	  asphyxiation	  or	  aspiration	  pneumonia	  because	  of	  
weakness	  of	  the	  bulbar	  musculature	  (Kennedy	  et	  al.,	  1968;	  Atsuta	  et	  al.,	  2006).	  This	  
is	  the	  only	  life-­‐threatening	  complication	  in	  SBMA.	  	  
Dysarthria,	  dysphagia,	  and	  the	  onset	  age	  of	  pneumonia	  significantly	  correlates	  with	  
the	  number	  of	  CAG	  repeats	  (Atsuta	  et	  al.,	  2006).	  Since	  bulbar	  symptoms	  most	  
strongly	  affect	  prognosis,	  videofluorography-­‐assessed	  pharyngeal	  barium	  residue	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has	  been	  used	  as	  primary	  or	  secondary	  outcome	  measure	  in	  SBMA	  clinical	  trials	  
(Katsuno	  et	  al.,	  2010;	  Fernandez-­‐Rhodes	  et	  al.,	  2011).	  
	  
Differential	  Diagnosis	  
The	  diagnosis	  of	  SBMA	  is	  delayed	  for	  many	  patients	  due	  to	  decreased	  
awareness	  of	  the	  disease.	  With	  the	  availability	  of	  genetic	  testing,	  and	  recognition	  of	  
the	  key	  characteristic	  clinical	  features,	  a	  diagnosis	  can	  be	  relatively	  straightforward.	  
The	  time	  to	  diagnosis	  will	  typically	  be	  postponed	  for	  5.5	  years	  on	  average,	  and	  
subjects	  will	  wait	  3.5	  years	  from	  the	  onset	  of	  weakness	  to	  the	  time	  they	  are	  first	  
medically	  evaluated	  (Rhodes	  et	  al,	  2009).	  If	  a	  misdiagnosis	  occurs,	  SBMA	  patients	  
are	  most	  likely	  initially	  diagnosed	  with	  amyotrophic	  lateral	  sclerosis	  (ALS).	  
Dysphagia	  and	  dysarthria	  are	  a	  common	  finding	  in	  ALS;	  nevertheless,	  differentiation	  
of	  ALS	  from	  SBMA	  can	  usually	  be	  made	  based	  on	  history	  and	  physical	  examination.	  
Individuals	  with	  ALS	  usually	  display	  upper	  and	  lower	  motor	  neuron	  signs	  as	  well	  as	  a	  
more	  rapid	  disease	  progression.	  Jaw	  drop,	  jaw	  and	  orbicularis	  oris	  weakness,	  and	  
ptosis	  in	  middle-­‐aged	  men	  are	  more	  frequently	  associated	  with	  myasthenia	  gravis.	  
However,	  negative	  antiacetylcholine	  receptor	  antibody,	  together	  with	  lack	  of	  
improvement	  with	  MG	  specific	  therapies	  (pyridostigmine,	  corticosteroids	  or	  other	  
immunosuppressants)	  can	  help	  in	  the	  diagnosis.	  It	  is	  common	  for	  people	  with	  
different	  myopathies	  (i.e.	  myotonic	  dystrophy	  or	  facioscapulohumeral	  muscular	  
dystrophy)	  to	  develop	  a	  nasal	  voice	  and	  swallowing	  problems.	  Some	  suffer	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weakness	  in	  their	  diaphragm	  and	  chest	  muscles,	  which	  results	  in	  breathing	  
problems.	  Electrophysiology,	  serum	  CK	  concentration,	  and/or	  muscle	  biopsy	  are	  
often	  warranted	  to	  differentiate	  the	  disease	  from	  motor	  neuron	  disease..	  
	  
Management	  
There	  is	  currently	  no	  treatment	  available	  to	  alter	  the	  course	  of	  the	  disease.	  
Animal	  models	  can	  recapitulate	  some	  aspects	  of	  the	  disease	  phenotype,	  and	  
androgen	  reduction	  therapy	  in	  these	  animals	  has	  been	  effective	  (Katsuno	  et	  al,	  
2003).	  Testing	  of	  the	  androgen	  reducing	  agents	  leuprorelin	  and	  dutasteride	  in	  
placebo	  controlled,	  randomized,	  clinical	  trials	  has	  not	  shown	  significant	  effects	  on	  
the	  primary	  outcome	  measures	  (Fernandez-­‐Rhodes	  et	  al,	  2011;	  Banno	  et	  al,	  2009;	  
Katsuno	  et	  al,	  2010).	  SBMA	  management	  should	  be	  focused	  on	  enhancing	  mobility	  
and	  function	  while	  also	  preventing	  complications	  of	  the	  disease.	  Subjects	  who	  
describe	  choking	  spells	  or	  dysphagia	  should	  undergo	  a	  speech	  and	  swallow	  
evaluation	  to	  evaluate	  for	  bulbar	  dysfunction.	  Behavioral	  changes	  can	  be	  instituted	  
to	  reduce	  the	  risk	  of	  aspiration.	  	  While	  dyspnea	  is	  not	  typically	  encountered	  in	  
SBMA,	  pulmonary	  function	  testing	  should	  be	  done	  in	  those	  subjects	  experiencing	  
shortness	  of	  breath.	  Mobility	  and	  ambulation	  can	  be	  enhanced	  with	  a	  physical	  




	  The	  effect	  of	  activity	  level	  on	  function	  in	  SBMA	  remains	  uncertain.	  A	  study	  
of	  moderate-­‐intensity	  aerobic	  exercise	  in	  eight	  SBMA	  subjects	  by	  Preisler	  et	  al.	  
showed	  mixed	  results	  with	  an	  increase	  in	  maximal	  work	  capacity,	  but	  no	  effect	  on	  
maximal	  oxygen	  uptake.	  	  Given	  the	  variability	  in	  function	  across	  the	  SBMA	  
population,	  exercise	  needs	  to	  be	  tailored	  to	  the	  patient’s	  level	  of	  function.	  Although	  
we	  would	  expect	  exercise	  to	  help	  maintain	  and	  improve	  mobility,	  more	  studies	  are	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Figure	  Legends	  	  
	  
Figure	  1.	  Video	  swallow	  study	  in	  a	  patient	  with	  Kennedy’s	  Disease	  showing	  before	  
(a.)	  and	  after	  (b.)	  swallow	  with	  retention	  of	  bolus	  at	  the	  base	  of	  the	  tongue	  and	  
post-­‐cricoid	  regions.	  Slow	  propulsion	  of	  liquid	  in	  the	  upper	  esophagus	  prior	  to	  the	  
aortic	  arch	  (c.).	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  Case.	  	  We	  report	  the	  case	  of	  a	  29-­‐year-­‐old	  male	  who	  had	  muscle	  weakness	  in	  his	  
thighs,	  fatigue	  after	  exercise,	  fasciculations,	  cramping,	  and	  tremor	  since	  age	  18.	  He	  
has	  also	  had	  burning	  neuropathic	  pain	  with	  dysesthesia	  in	  the	  distal	  lower	  
extremities	  for	  the	  past	  two	  years.	  He	  occasionally	  takes	  ibuprofen	  to	  alleviate	  the	  
pain	  in	  his	  feet.	  He	  has	  no	  difficulty	  with	  swallowing,	  however,	  he	  does	  experience	  
fatigue	  in	  the	  muscles	  of	  mastication	  after	  a	  meal.	  He	  will	  occasionally	  experience	  
phlegm	  building	  up	  in	  his	  throat,	  although	  he	  has	  not	  had	  difficulty	  with	  choking.	  In	  
addition	  to	  the	  neurological	  features,	  he	  had	  a	  congenital	  abnormality	  of	  the	  penis	  
(chordee),	  which	  was	  repaired	  at	  age	  7.	  He	  also	  has	  bilateral	  testicular	  atrophy.	  By	  
age	  16	  he	  developed	  gynecomastia,	  which	  became	  socially	  stigmatizing.	  He	  has	  a	  
pertinent	  family	  history	  of	  a	  maternal	  second	  cousin	  with	  similar	  neuromuscular	  
symptoms	  at	  age	  19.	  	  
On	  examination	  the	  patient	  had	  pronounced	  gynecomastia	  bilaterally.	  
Fibrillations	  and	  atrophy	  were	  noted	  in	  the	  tongue,	  and	  weakness	  was	  also	  
observed	  in	  the	  orbicularis	  oculi	  and	  orbicularis	  oris.	  Limb	  weakness	  was	  severe	  in	  
the	  shoulders,	  thighs,	  and	  toes	  bilaterally.	  Sensory	  testing	  showed	  a	  loss	  of	  
temperature	  and	  vibratory	  sensation	  in	  the	  fingers	  and	  toes	  with	  a	  length-­‐
dependent	  gradient.	  On	  gait	  testing	  he	  had	  difficulty	  standing	  on	  his	  heels	  or	  toes.	  
Abnormalities	  in	  quantitative	  muscle	  strength	  testing	  and	  muscle	  MRI	  were	  also	  
detected	  (figure,	  A	  &	  B),	  demonstrating	  the	  extent	  of	  disease	  involvement	  at	  a	  
relatively	  early	  age.	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Detection	  of	  a	  68	  CAG	  repeat	  expansion	  in	  the	  androgen	  receptor.	  Sequencing	  
and	  PCR	  analysis	  of	  genomic	  DNA	  isolated	  from	  the	  patient’s	  venous	  blood	  and	  
forearm	  skin	  fibroblasts	  showed	  a	  repeat	  length	  of	  68	  CAGs	  in	  both	  samples.	  Figure	  
C	  shows	  a	  DNA	  fragment	  obtained	  by	  PCR	  with	  primers	  flanking	  the	  CAG	  repeat	  run	  
on	  a	  20%	  acrylamide	  gel	  with	  a	  DNA	  fragment	  obtained	  from	  a	  different	  patient	  
containing	  62	  CAGs.	  Sequencing	  of	  the	  remaining	  androgen	  receptor	  open	  reading	  
frame	  of	  this	  individual	  was	  done	  and	  no	  other	  genetic	  variants	  were	  found.	  In	  
particular,	  the	  glycine	  repeat	  length	  was	  in	  the	  normal	  range.3	  Androgen	  receptor	  
protein	  levels	  in	  patient-­‐derived	  fibroblasts	  were	  comparable	  to	  control	  samples	  
with	  non-­‐expanded	  androgen	  receptor	  (figure,	  D).	  	  
	  
Discussion.	  Patients	  with	  SBMA	  usually	  present	  with	  the	  onset	  of	  weakness	  in	  
their	  mid-­‐forties	  and	  have	  an	  average	  androgen	  receptor	  repeat	  length	  of	  47	  CAGs.2	  
Here	  we	  describe	  a	  patient	  with	  a	  68	  CAG	  repeat	  who	  has	  an	  onset	  of	  weakness	  
beginning	  at	  age	  18	  and	  additional	  features	  of	  disease	  which	  have	  not	  previously	  
been	  reported,	  including	  abnormalities	  in	  sexual	  development	  and	  neuropathic	  
pain.	  The	  identification	  of	  a	  patient	  with	  68	  CAGs	  expands	  the	  spectrum	  of	  disease	  
features	  associated	  with	  SBMA,	  as	  the	  disease	  has	  previously	  been	  reported	  in	  
patients	  with	  62	  CAGs	  or	  less.	  	  
The	  association	  of	  a	  polyglutamine	  repeat	  expansion	  in	  the	  androgen	  receptor	  
with	  a	  chordee	  deformity	  is	  novel	  but	  not	  unexpected,	  given	  the	  known	  expression	  
of	  androgen	  receptor	  in	  sexually	  dimorphic	  tissues.	  Features	  of	  androgen	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insensitivity	  including	  infertility,	  gynecomastia,	  and	  reduced	  androgenic	  alopecia4	  
have	  been	  described	  in	  SBMA.	  It	  is	  possible	  that	  the	  additional	  findings	  of	  chordee	  
and	  probable	  small	  fiber	  neuropathy	  observed	  in	  this	  patient	  are	  due	  to	  the	  larger	  
expansion	  of	  the	  polyglutamine	  repeat.	  Ogata	  et	  al.5	  reported	  the	  identification	  of	  a	  
44	  CAG	  repeat	  in	  the	  androgen	  receptor	  of	  an	  11	  year	  old	  boy	  with	  under-­‐
masculinized	  genitalia	  and	  chordee	  without	  neuromuscular	  disease.	  	  The	  diagnosis	  
of	  5a-­‐reductase	  deficiency	  has	  also	  been	  reported	  in	  a	  pediatric	  male	  patient	  with	  
chordee	  and	  normal	  androgen	  receptor	  studies.6	  Treatment	  of	  this	  infant	  with	  
dihydrotestosterone	  and	  surgical	  release	  of	  chordee	  resulted	  in	  improvement	  of	  
symptoms.	  Collectively,	  these	  findings	  emphasize	  that	  the	  CAG	  repeat	  expansion	  in	  
the	  androgen	  receptor	  gene	  is	  capable	  of	  altering	  androgen-­‐dependent	  signaling	  
pathways.	  Our	  observations	  further	  suggest	  that	  the	  CAG	  expansion	  mutation	  may	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Figure	  Legends	  
Figure	  1.	  Phenotypical	  features	  and	  androgen	  receptor	  characterization.	  
Quantitative	  muscle	  strength	  testing	  in	  12	  different	  muscle	  groups	  shows	  the	  
degree	  of	  muscle	  weakness	  (in	  kg)	  as	  compared	  to	  controls	  matched	  for	  age,	  
height,	  weight,	  and	  body	  size	  (A).	  T1	  STIR	  MRI	  image	  of	  the	  thighs	  showing	  patchy	  
areas	  of	  hyperintensity	  indicative	  of	  muscle	  injury	  and	  degeneration	  (B).	  PCR	  
products	  from	  patient	  DNA	  were	  generated	  using	  primers	  that	  bracket	  the	  CAG	  
expansion.	  Acrylamide	  gel	  electrophoresis	  shows	  the	  band	  shift	  relative	  to	  a	  62	  CAG	  
sample	  from	  a	  different	  patient	  (C).	  Androgen	  receptor	  expression	  is	  equal	  in	  
patient	  derived	  fibroblast	  cultures	  when	  compared	  to	  control	  samples	  on	  western	  
blotting.	  	  Dihydrotestosterone	  (DHT)	  treatment	  results	  in	  similar	  upregulation	  of	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Spinal	  and	  bulbar	  muscular	  atrophy	  (SBMA,	  Kennedy’s	  disease)	  is	  an	  X-­‐linked	  
neurodegenerative	  disorder	  caused	  by	  expansion	  of	  a	  polyglutamine	  tract	  in	  the	  
androgen	  receptor	  (AR).1	  The	  repeat	  expansion	  mutation	  confers	  a	  toxic	  gain	  of	  
function	  on	  the	  mutant	  AR	  protein	  and	  results	  in	  its	  aggregation	  and	  accumulation	  
into	  inclusions.2	  The	  disease	  is	  clinically	  characterized	  by	  late-­‐onset	  weakness	  and	  
atrophy	  of	  extremity	  and	  bulbar	  muscles	  due	  to	  lower	  motor	  neuron	  degeneration	  
in	  the	  spinal	  cord	  and	  brainstem;	  there	  is	  also	  evidence	  of	  	  primary	  skeletal	  muscle	  
involvement.3	  Signs	  of	  androgen	  insensitivity	  are	  frequently	  observed.4	  Post-­‐
translational	  modification	  of	  the	  disease	  protein	  affects	  its	  toxicity.5,6	  We	  recently	  
showed	  that	  insulin-­‐like	  growth	  factor	  1	  (IGF-­‐1)	  modifies	  mutant	  AR	  toxicity	  via	  Akt	  
phosphorylation	  in	  vitro7	  and	  that	  SBMA	  model	  mice	  overexpressing	  the	  non-­‐
circulating	  muscle-­‐specific	  isoform	  of	  IGF-­‐1	  have	  a	  less	  severe	  phenotype.8	  
In	  the	  present	  study,	  we	  explored	  the	  efficacy	  of	  parenteral	  administration	  of	  
recombinant	  human	  IGF-­‐1	  and	  IGF-­‐1	  binding	  protein	  3	  (rhIGF-­‐1/IGFBP3)	  in	  SBMA	  
mice.	  In	  order	  to	  have	  clinically	  meaningful	  results,	  we	  designed	  the	  study	  in	  a	  
randomized,	  controlled,	  blinded	  fashion,	  and	  the	  treatment	  was	  started	  after	  the	  
onset	  of	  disease	  manifestations.	  
	  
Materials	  and	  Methods	  
76	  
	  
Animals	  and	  drug	  treatment.	  The	  study	  was	  carried	  out	  in	  accordance	  with	  the	  NIH	  
Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals,	  and	  was	  approved	  by	  the	  NINDS	  
Animal	  Care	  Committee.	  Transgenic	  mice	  expressing	  mutant	  AR	  with	  a	  97	  
glutamine	  repeat	  (AR97Q)	  were	  used.9	  The	  mice	  were	  genotyped	  by	  PCR	  with	  tail	  
DNA	  as	  previously	  described.9	  Recombinant	  human	  IGF-­‐1	  in	  complex	  with	  IGFBP-­‐3	  
(Iplex,	  mecasermin	  rinfabate)	  was	  provided	  by	  Insmed	  Inc.	  A	  vehicle	  solution	  was	  
used	  as	  control.	  The	  injections	  and	  all	  the	  analyses	  were	  performed	  by	  blinded	  
investigators.	  
Behavioral	  and	  survival	  analysis.	  A	  hanging	  wire	  test	  was	  performed	  as	  
previously	  described.10	  We	  assessed	  the	  gait	  using	  the	  Gait	  Analysis	  Treadmill	  
(Columbus	  Instruments)	  and	  TreadScan	  software	  (CleverSys).	  For	  survival	  analysis,	  
mice	  were	  sacrificed	  when	  they	  had	  lost	  more	  than	  30%	  of	  body	  weight,	  or	  showed	  
inability	  to	  move	  or	  signs	  of	  dehydration.	  
Biochemical	  analysis.	  16	  week	  old	  mice	  were	  anesthetized	  with	  isoflurane	  and	  
sacrificed.	  Quadriceps	  muscles	  and	  spinal	  cord	  were	  dissected	  and	  snap-­‐frozen	  in	  
liquid	  nitrogen.	  Using	  a	  polytron	  homogenizer,	  tissue	  samples	  were	  processed	  in	  
ice-­‐cold	  homogenization	  buffer	  (150	  mM	  NaCl,	  50	  mM	  Tris,	  2	  mM	  EDTA,	  1%	  sodium	  
deoxycholate,	  0.5%	  Triton	  X-­‐100,	  0.1%	  sodium	  dodecyl	  sulfate)	  containing	  protease	  
and	  phosphatase	  inhibitor	  cocktails	  (Roche).	  The	  homogenates	  were	  sonicated	  and	  
pre-­‐cleared	  at	  4,000	  x	  g	  for	  10	  min	  at	  4oC.	  Protein	  lysates	  were	  separated	  on	  Tris-­‐
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the	  following	  antibodies:	  AR	  H-­‐280	  (sc-­‐13062,	  Santa	  Cruz),	  phospho-­‐Akt	  and	  total	  
Akt	  (9271	  and	  9272,	  respectively,	  Cell	  Signaling),	  choline	  acetyltransferase	  (AB144P,	  
Chemicon),	  and	  alpha-­‐tubulin	  as	  a	  loading	  control	  (T6199,	  Sigma).	  Western	  blots	  
were	  visualized	  with	  peroxidase-­‐linked	  secondary	  antibodies	  (R&D	  Systems)	  by	  
chemiluminescence	  detection	  (PerkinElmer	  Life	  Sciences).	  Quantification	  was	  done	  
with	  ImageJ	  software.	  
Histological	  analysis.	  6-­‐8	  μm	  sections	  of	  unfixed,	  snap	  frozen	  quadriceps	  muscle	  
from	  16	  week	  old	  mice	  were	  cut	  with	  a	  -­‐20˚C	  cryostat	  and	  processed	  for	  
hematoxylin	  and	  eosin	  or	  nicotinamide	  adenine	  dinucleotide	  staining.	  For	  
immunofluorescence,	  sections	  were	  fixed	  with	  4%	  PFA	  and	  incubated	  overnight	  at	  
4˚C	  with	  rabbit	  anti-­‐laminin	  (1:80,	  SIGMA-­‐Aldrich).	  Digital	  images	  were	  captured	  
using	  a	  Zeiss	  Axiovert	  100M	  microscope	  and	  analyzed	  with	  NIS	  Elements	  software.	  
8	  μm	  thick	  tissue	  sections	  were	  fixed	  in	  4%	  paraformadehyde,	  stained	  with	  mouse	  
1C2	  antibody	  (1:20000;	  Chemicon)	  and	  counterstained	  with	  Mayer’s	  hematoxylin.	  
For	  muscle	  morphology,	  more	  than	  500	  fibers	  were	  counted	  in	  randomly	  selected	  
areas.	  For	  motor	  neuron	  counts,	  spinal	  cords	  from	  anesthetized	  mice	  were	  
collected	  and	  post-­‐fixed	  for	  12	  h	  in	  4%	  PFA.	  Paraffin-­‐embedded	  samples	  were	  
serially	  sectioned	  at	  6	  μm	  steps,	  mounted	  on	  slides,	  and	  processed	  for	  Nissl	  
staining.	  Images	  of	  ten	  contiguous	  sections,	  100	  μm	  apart	  (original	  magnification,	  
10×)	  were	  analyzed.	  Motor	  neurons	  were	  identified	  as	  cells	  with	  Nissl	  staining,	  clear	  
nucleus	  and	  nucleolus,	  and	  a	  maximum	  diameter	  greater	  than	  25	  µm.	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Statistical	  analysis.	  A	  two-­‐way	  mixed	  design	  ANOVA	  was	  done	  to	  assess	  the	  
effects	  of	  treatment	  on	  hanging	  wire	  performance	  and	  body	  weight	  over	  time.	  A	  log	  
rank	  test	  was	  used	  to	  compare	  Kaplan-­‐Meier	  survival	  in	  treated	  versus	  non-­‐treated	  
AR97Q	  mice.	  A	  two-­‐tailed	  Student’s	  t	  test	  or,	  for	  data	  not	  normally	  distributed,	  a	  
Mann-­‐Whitney	  U	  test	  was	  performed	  to	  compare	  differences	  between	  two	  groups.	  




IGF-­‐1	  activates	  Akt	  and	  reduces	  mutant	  AR	  aggregation	  in	  muscle.	  To	  investigate	  
whether	  IGF-­‐1	  treatment	  is	  effective	  in	  SBMA	  mice,	  we	  randomized	  a	  cohort	  of	  
male	  AR97Q	  mice	  to	  receive	  by	  daily	  intraperitoneal	  injections	  of	  either	  vehicle	  or	  
rhIGF-­‐1/IGFBP3	  (15	  mg/kg).	  This	  agent	  mimics	  the	  biological	  effects	  of	  IGF-­‐1	  alone,	  
but	  has	  a	  more	  favorable	  pharmacokinetic	  profile.11	  We	  started	  treatment	  at	  age	  10	  
weeks,	  after	  the	  usual	  onset	  of	  disease	  manifestations.9	  IGF-­‐1	  resulted	  in	  a	  
significant	  increase	  in	  Akt	  phosphorylation	  at	  serine	  473	  (p	  <	  0.01;	  Fig	  1A)	  and	  also	  
reduced	  the	  accumulation	  of	  both	  monomeric	  and	  aggregated	  mutant	  AR	  (p	  <	  0.05,	  
p	  <	  0.01;	  Fig	  1B)	  in	  skeletal	  muscle.	  To	  assess	  whether	  IGF-­‐1	  affects	  the	  
accumulation	  of	  mutant	  AR	  into	  nuclear	  inclusions,	  cross-­‐sections	  of	  quadriceps	  
muscle	  were	  stained	  with	  the	  polyglutamine-­‐specific	  antibody	  1C2.	  IGF-­‐1	  reduced	  
the	  number	  of	  1C2-­‐positive	  nuclei	  by	  about	  half	  (p	  =	  0.03;	  Fig	  1C).	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No	  changes	  in	  the	  level	  of	  Akt	  phosphorylation	  (Supplemental	  Fig	  1A)	  and	  the	  
accumulation	  of	  monomeric	  and	  aggregated	  mutant	  AR	  (Supplemental	  Fig	  1B)	  were	  
detected	  in	  spinal	  cord	  lysates.	  To	  further	  characterize	  the	  effects	  of	  IGF-­‐1	  on	  the	  
motor	  neurons,	  we	  analyzed	  spinal	  cord	  levels	  of	  choline	  acetyltransferase	  (ChAT),	  
a	  cholinergic	  neuron	  marker.	  ChAT	  levels	  were	  higher	  in	  IGF-­‐1	  treated	  mice	  than	  in	  
vehicle-­‐treated	  animals	  (p	  =	  0.01;	  Supplementary	  Fig	  1C)	  and	  comparable	  to	  wild	  
type	  littermates	  (not	  shown).	  
IGF-­‐1	  administration	  attenuates	  disease	  manifestations	  in	  SBMA	  mice.	  Forty	  
male	  transgenic	  mice	  were	  randomly	  assigned	  to	  receive	  either	  vehicle	  or	  IGF-­‐1	  
from	  10	  through	  20	  weeks	  of	  age,	  as	  described	  above.	  IGF-­‐1	  treated	  SBMA	  mice	  
had	  less	  body	  weight	  loss	  (p	  =	  0.001;	  Fig	  2A	  and	  B)	  and	  increased	  grip	  strength	  (p	  =	  
0.001;	  Fig	  2C).	  Gait	  analysis	  at	  week	  16,	  showed	  longer	  stride	  time	  and	  length	  and	  
reduced	  rear	  track	  width	  and	  paw	  area	  in	  the	  IGF-­‐1	  treated	  SBMA	  mice	  (Fig	  2D).	  
Mice	  treated	  with	  IGF-­‐1	  lived	  ~3	  weeks	  longer	  on	  average	  than	  vehicle-­‐treated	  
mice,	  although	  this	  did	  not	  reach	  statistical	  significance	  (p	  =	  0.09;	  Fig	  2E),	  in	  part	  
because	  a	  subset	  of	  the	  mice	  were	  already	  severely	  affected	  before	  the	  beginning	  
of	  treatment.	  A	  post	  hoc	  analysis	  excluding	  these	  mice	  (hunched	  posture	  and	  
sustained	  weight	  loss	  >	  5%	  at	  week	  10)	  showed	  a	  significant	  difference	  between	  the	  
remaining	  animals	  in	  the	  two	  groups	  (p	  =	  0.02;	  Supplemental	  Fig	  1D).	  	  
IGF-­‐1	  reduces	  muscle	  pathology	  in	  AR97Q	  mice.	  To	  investigate	  the	  effects	  of	  
IGF-­‐1	  treatment	  on	  muscle	  pathology,	  quadriceps	  muscles	  were	  collected	  from	  16	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week	  old	  SBMA	  mice	  and	  wild	  type	  littermates	  treated	  with	  vehicle	  or	  IGF-­‐1.	  
Muscle	  cross-­‐sections	  of	  vehicle-­‐treated	  AR97Q	  mice	  showed	  angulated	  myofibers	  
and	  grouped	  atrophic	  fibers,	  as	  well	  as	  fibers	  with	  central	  nuclei	  (Fig	  3A-­‐B).	  These	  
signs	  of	  muscle	  atrophy	  and	  degeneration	  were	  markedly	  reduced	  in	  the	  IGF-­‐1-­‐
treated	  mice.	  The	  mean	  cross-­‐sectional	  area	  and	  minimal	  diameter	  of	  myofibers	  
were	  also	  increased	  compared	  to	  vehicle-­‐treated	  mice	  (p	  =	  0.01,	  0.03,	  respectively;	  
Fig	  3C-­‐E).	  There	  was	  a	  slight	  increase	  in	  the	  number	  of	  anterior	  horn	  cells	  in	  mice	  
treated	  with	  IGF-­‐1,	  but	  it	  did	  not	  reach	  statistical	  significance	  (p	  =	  0.09;	  
Supplementary	  Fig	  1E).	  This	  is	  not	  surprising	  since	  the	  motor	  neuron	  count	  is	  not	  
significantly	  reduced	  in	  this	  mouse	  model.9	  
	  	  
Discussion	  
In	  this	  study,	  we	  evaluated	  the	  effects	  of	  parenteral	  administration	  of	  IGF-­‐1	  in	  a	  
mouse	  model	  of	  SBMA.	  IGF-­‐1	  improved	  motor	  performance,	  attenuated	  weight	  
loss,	  and	  improved	  muscle	  pathology	  in	  SBMA	  mice.	  It	  also	  had	  indirect	  effects	  on	  
motor	  neurons,	  as	  suggested	  by	  the	  increase	  in	  ChAT	  expression	  in	  IGF-­‐1-­‐treated	  
mice.	  Peripheral	  delivery	  of	  IGF-­‐1	  results	  in	  very	  low	  concentrations	  in	  brain,	  but	  
skeletal	  muscle	  is	  a	  source	  of	  signals	  that	  influence	  motor	  neuron	  maintenance.12	  
IGF-­‐1	  and	  other	  trophic	  factors	  have	  been	  evaluated	  as	  potential	  treatments	  for	  
amyotrophic	  lateral	  sclerosis,	  due	  to	  their	  effects	  on	  promoting	  muscle	  growth13	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and	  motor	  neuron	  survival.14	  However,	  the	  response	  of	  this	  disease	  to	  IGF-­‐1	  
therapy	  has	  been	  not	  beneficial	  to	  date.15,16,17.	  
SBMA	  may	  be	  a	  better	  candidate	  for	  IGF-­‐1	  administration	  for	  two	  reasons:	  1)	  
IGF-­‐1,	  via	  Akt	  phosphorylation,	  specifically	  reduces	  the	  toxicity	  of	  mutant	  AR;7,8	  and	  
2)	  muscle	  has	  a	  role	  in	  the	  pathogenesis	  of	  SBMA.	  Muscle	  biopsies	  from	  SBMA	  
patients	  show	  myogenic	  changes	  as	  well	  as	  neurogenic	  atrophy;18	  muscle	  pathology	  
precedes	  spinal	  cord	  pathology	  in	  a	  knockin	  mouse	  model	  of	  SBMA;19	  and	  muscle-­‐
specific	  overexpression	  of	  wild	  type	  AR	  leads	  to	  an	  SBMA-­‐like	  phenotype.20	  
Our	  study	  indicates	  that	  peripheral	  delivery	  of	  IGF-­‐1	  in	  SBMA	  mice	  has	  benefit	  
after	  the	  onset	  of	  disease	  manifestations.	  These	  results	  provide	  a	  pre-­‐clinical	  basis	  
for	  further	  examining	  IGF-­‐1	  in	  SBMA	  patients.	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Figure	  1.	  IGF-­‐1	  increases	  phosphorylation	  of	  Akt	  and	  decreases	  AR	  aggregation	  in	  
SBMA	  muscle.	  (A)	  Western	  blot	  analysis	  of	  Akt	  phosphorylation	  in	  skeletal	  muscle.	  
Quantification	  of	  Akt,	  showing	  the	  mean	  with	  standard	  deviation.	  Unpaired	  t-­‐test	  **	  
p	  <	  0.01	  (n	  =	  5).	  (B)	  Western	  blot	  analysis	  of	  AR	  protein	  levels	  in	  skeletal	  muscle.	  
Quantification,	  showing	  the	  mean	  with	  standard	  deviation.	  Unpaired	  t-­‐test,	  *	  p	  <	  
0.05;	  **	  p	  <	  0.01	  (n	  =	  5).	  (C)	  Immunohistochemical	  analysis	  using	  1C2	  antibody	  on	  
cross	  sections	  of	  AR97Q	  muscle	  shows	  a	  reduction	  of	  diffuse	  nuclear	  staining	  and	  
nuclear	  inclusions	  in	  IGF-­‐1	  compared	  to	  vehicle-­‐treated	  mice.	  Graphs,	  mean	  ±	  SEM;	  *	  
p	  =	  0.03.	  Scale	  bar,	  20	  µm.	  
Figure	  2.	  IGF-­‐1	  attenuates	  weight	  loss,	  enhances	  motor	  behavior,	  and	  increases	  
survival	  of	  SBMA	  mice.	  (A)	  Two	  mice	  from	  the	  same	  litter	  at	  week	  16	  of	  age,	  
showing	  the	  gross	  appearance	  of	  an	  IGF-­‐1	  treated	  (left)	  and	  vehicle-­‐treated	  (right)	  
SBMA	  mouse.	  (B	  and	  C)	  IGF-­‐1	  treated	  SBMA	  (n	  =	  20)	  mice	  had	  less	  body	  weight	  loss	  
(p	  =	  0.001)	  and	  increased	  grip	  strength	  (p	  =	  0.001)	  compared	  to	  vehicle-­‐treated	  
mice	  (n	  =	  20).	  Scale	  bars,	  SEM.	  (D)	  TreadScan	  assessment	  showed	  improved	  motor	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performance	  in	  AR97Q	  mice	  treated	  with	  IGF-­‐1	  	  (n	  =	  6)	  compared	  to	  vehicle	  (n	  =	  6).	  
Scale	  bars,	  SEM.	  Unpaired	  t-­‐test	  **	  p	  <	  0.01;	  *	  p	  <	  0.05	  (E)	  Kaplan-­‐Meier	  survival	  
curves	  of	  mice	  treated	  with	  IGF-­‐1	  (n	  =	  20)	  or	  vehicle	  (n	  =20).	  P	  =	  0.09,	  log-­‐rank	  test.	  
Figure	  3.	  IGF-­‐1	  ameliorates	  SBMA	  muscle	  pathology.	  (A)	  Hematoxylin	  and	  eosin	  
staining.	  Arrows	  =	  fibers	  with	  central	  nuclei;	  asterisks	  =	  angulated	  and	  grouped	  
fibers.	  (B)	  Nicotinamide	  adenine	  dinucleotide	  staining.	  Asterisks	  =	  moth-­‐eaten	  
fibers.	  (C)	  Histograms	  of	  myofiber	  cross-­‐sectional	  area	  (CSA).	  (D)	  Muscle	  cross-­‐
sectional	  area	  (CSA)	  and	  (E)	  minimal	  Feret’s	  diameter	  were	  increased	  in	  SBMA	  mice	  
treated	  with	  IGF-­‐1	  compared	  with	  vehicle	  (p	  =	  0.01	  and	  p	  =	  0.03,	  respectively).	  
Shown	  are	  transverse	  sections	  of	  quadriceps	  of	  16-­‐week-­‐old	  SBMA	  mice	  and	  wild-­‐
type	  littermates.	  	  
Supplementary	  Figure	  1.	  IGF-­‐1	  effects	  on	  spinal	  cord	  pathology	  in	  SBMA	  Mice.	  (A)	  
Western	  blot	  of	  Akt	  phosphorylation	  in	  spinal	  cord.	  Quantification	  of	  Akt,	  showing	  
the	  mean	  with	  standard	  deviation.	  Unpaired	  t-­‐test,	  p	  =	  1.00.	  (B)	  Western	  blot	  of	  AR	  
protein	  levels	  in	  spinal	  cord	  of	  AR97Q	  mice.	  Quantification	  for	  mutant	  AR	  and	  of	  the	  
AR	  aggregates,	  showing	  the	  mean	  with	  standard	  deviation.	  Unpaired	  t-­‐test,	  p	  =	  0.18	  
and	  p	  =	  0.13,	  respectively.	  (C)	  Western	  blot	  of	  ChAT	  levels	  in	  spinal	  cord.	  
Quantification	  of	  ChAT	  level,	  showing	  the	  mean	  with	  standard	  deviation.	  Unpaired	  
t-­‐test,	  *	  p	  =	  0.01.	  (D)	  Kaplan-­‐Meier	  survival	  curves	  of	  mice	  treated	  with	  IGF-­‐1	  (n	  =	  
16)	  or	  vehicle	  (n	  =	  18)	  receiving	  at	  least	  5	  weeks	  of	  treatment.	  P	  =	  0.02,	  log-­‐rank	  
test.	  (E)	  Nissl-­‐stained	  transverse	  sections	  of	  ventral	  spinal	  cords	  of	  16-­‐week-­‐old	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mice.	  Quantitative	  analysis	  suggested	  an	  increase	  in	  the	  number	  of	  motor	  neurons	  
per	  section	  is	  slightly	  increased	  in	  AR97Q	  mice	  treated	  with	  IGF-­‐1	  as	  compared	  to	  
vehicle,	  but	  this	  did	  not	  reach	  statistical	  significance	  (p	  =	  0.09).	  Graphs,	  mean	  ±	  







































Supplementary Figure 1. IGF-1 effects on spinal cord pathology in SBMA Mice. 
(A) Western blot of Akt phosphorylation in spinal cord. Quantification of Akt, 
showing the mean with standard deviation. Unpaired t-test, p = 1.00. (B) Western 
blot of AR protein levels in spinal cord of AR97Q mice. Quantification for mutant AR 
and of the AR aggregates, showing the mean with standard deviation. Unpaired t-
test, p = 0.18 and p = 0.13, respectively. (C) Western blot of ChAT levels in spinal 
cord. Quantification of ChAT level, showing the mean with standard deviation. 
Unpaired t-test, * p = 0.01. (D) Kaplan-Meier survival curves of mice treated with 
IGF-1 (n = 16) or vehicle (n = 18) receiving at least 5 weeks of treatment. P = 0.02, 
log-rank test. (E) Nissl-stained transverse sections of ventral spinal cords of 16-
week-old mice. Quantitative analysis suggested an increase in the number of motor 
neurons per section is slightly increased in AR97Q mice treated with IGF-1 as 
compared to vehicle, but this did not reach statistical significance (p = 0.09). 
Graphs, mean ± SEM, n = 3.  
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